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PART 1 
Introduction 

Chapter 1 
Inflammatory bowel disease 
1.1 Clinical aspects of inflammatory bowel disease 
There are a number of different defmitions for inflammatory bowel disease (IBD) to 
be found in the literature. The defmition accepted by most researchers and clinicians is that 
the tenn inflammatory bowel disease comprises two, in practice, distinct entities: ulcerative 
colitis (UC) and Crohn's disease (CD)'. Both disorders are characterized by cbronic 
relapsing inflammation of parts of the gastrointestinal tract of unknown origin, causing 
abdominal pain and diarrhoea. Because of the recurrent pattern both diseases show signs of 
acute inflammation (e.g. influx of granulocytes out of the blood into the mucosa of the 
intestines) as well as signs of cbronic inflammation (e.g. infiltrates of lymphocytes and 
macrophages). 
Ulcerative colitis was 're-discovered' in the previous century by Wilks' and it 
became clear that UC was different from other known ulcerating diseases occurring in the 
large intestine such as dysentery and tuberculosis. UC is restricted to the large bowel and 
characterized by severe ulcerations, predominantly located in the rectum (90 % of the 
patients) and rectosigmoid (40 %), but sometimes affecting the entire colon (20 %y, The 
inflammation is limited to the mucosa, rendering it hyperaernic, edematous and friable in the 
acute phase. In most cases small mucosal haemorrhages and aphthoid ulcers can be seen 
macroscopically. Coalescence of these ulcers leads to irregular large ulcers. In the more 
serious cases parts of the mucosa may disappear and be replaced by granulation tissue 
which, in a later stage, may be covered with new epithelium. Islands of granulation tissue 
covered with epithelium may protrude into the lumen giving a cobblestone appearance 
(pseudopolyps). The mucosa bleeds easily giving rise to the main characteristic of UC, loss 
of blood with or without faeces. Histology shows infiltrates of inflammatory cells between 
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the crypts, diminished number of Goblet cells in the crypts and at the colon surface, edema 
of the mucosa and crypt abscesses (infiltrates of granulocytes in the wall and the lumen of 
the crypts). Particularly important in active colitis are the epithelial changes that appear in 
the margins of ulcers and often in the intervening mucosa. They consist of mucous depletion 
and inflammatory metaplasia. Even more important are varying degrees of atypical 
dysplasia, which may be classified as low to high grade'. The next step is the development 
of carcinoma. 
Symptoms depend on tile extent and seriousness of the inflanunation. In the case of 
proctitis the patients do not suffer from diarrhoea but their stools contain blood and mucus. 
In the case of a more extensive inflanunation patients suffer from diarrhoea that often 
consists of a mixture of faeces, blood and mucus, and colicky lower abdominal pain 
together with variable extraintestinal symptoms including fever and loss of weight. Grossly 
bloody stools and extraintestinal complications are far more common than with CD and the 
blood loss may be considerable'. 
In 1932 Crohn and associates described -what they considered- a new pathologic and 
clinical entity, regional ileitis6 . It is a non-specific, chronic, recurrent, granulomatous 
disease, affecting mainly young adults and characterized by a necrotizing ulcerating 
inflammatory process. In the long lasting cases formation of strictures is an important 
feature'. Nowadays the consensus is that CD may involve any portion of the gastrointestinal 
tract from mouth to anus, but most often the small intestine and colon are affected'. 
Diseased segments are separated by macroscopic normal tissue. This phenomena is called 
skip lesions. In contrast to UC, in CD the inflammation extends through the entire wall of 
the intestine into tile mesentery. In the transmural inflanunation the inflammatory cell 
popUlation consists primarily of lymphocytes and plasma cells. Noncaseating granulomas 
are found in 50 to 70 % of the cases during histologic examination of diseased intestinal 
segments or regional lymph nodes. If the terminal ileum is frequently involved in the 
inflannnation the increase of fibrous tissue in the wall may cause it to thicken. The fibrous 
tissue shrivels, causing stenosis of the lumen and the intestine may become a more or less 
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stiff tube. The mucosa may be marked by numerous linear ulcers in the long axis of the 
bowel, creating deep fissures, separated from each other by nodular mucosal thickenings 
that give a "cobblestone!! appearance, Penetrating ulcers may give rise to fistulous 
communications to adherent loops of bowel. These fistulas, so characteristic for CD, may 
penetrate to the skin or through the umbilicus or perineum'. 
The clinical presentation of CD is highly variable, depending On the age of the 
patient, the location and extent of the diseased bowel, and the acuteness of onset of the 
illness. If only the colon is affected diarrhoea will be the dominant symptom, often without 
any visible blood loss. In the case of a regional ileitis abdominal pain is prominent and 
diarrhoea often absent. The pain will be more profound if there is a clear stenosis of the 
intestine present, independent of the location of the inflanunation. 
Patients suffering from IBD often have extraintestinal symptoms and manifestations, 
examples are: erythema nodosum, pyoderma gangrenosum, intestinal peripheral arthritis, 
ankylosing spondylitis, sacroilitis, sclerosing cholangitis, chronic active hepatitis, anterior 
uveitis and even pericarditis or myocarditis'·'''. This might suggest that IBD is a systemic, 
rather than a purely gastrointestinal disorder. Some of tilese extraintestinal manifestations 
!Day even be life threatening. 
There are !Dany similarities between UC and CD, but there are also some clear 
differences 12, 
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Characteristic Crohn's disease (CD) Ulcerative colitis (UC) 
Small intestinal involvement alone 30-35% Never 
Combined small and large 50-60% Only large intestine 
Large intestinal involvement alone 20% Always 
Extraintestinal complications Yes Yes 
Familial predisposition Yes Yes 
Age, race, sex distribution Same as UC Same as CD 
Causation Unknown Unknown 
Nature of inflammatory reaction 
Ulcerations Numerous, linear, Coalescent, irregular, 
Transmural fibrosis ++++ Rare 
Granulomas +++ Rare 
Secondary cancers + +++ 
Table 1.1 Comparison of Crohn's disease and Ulcerative Colitis. 
1.2 Epidemiology of inflammatory bowel disease 
Inflammatory bowel disease has a world wide distribution, albeit with significant 
differences in prevalence and incidence between different areas of the globe. The incidence 
rates are highest in the northern countries such as the Scandinavian countries, Great Britain, 
U.S.A. and Canada, followed by Central Europe. In Africa, South America and Asia the 
incidence of lBD is very low". This implies the existence of a gradient from north to south. 
Even within the U.S.A. the reported rates in the northern states are higher than those of the 
southern states14 .1S . Another striking difference is that between urban and rural areas, with 
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the first having higher incidence rates than the second. Other epidemiological factors that 
influence the incidence and prevalence of mD are age, race, gender and socioeconomic 
status. Both UC and CD are primarily diseases of young adults, as far as the age of onset is 
concerned. Nevertheless some studies report a bimodal distribution, with the largest peak 
between the ages of 15 and 25 and a smaller one in the sixth decade of life 16.17. Some 
authors, however, suggest that the second peak might be an artefact caused by uncommon 
presentations of other gastrointestinal diseases such as ischemic bowel disease or 
diverticulitis IS , 
Although the manifestations are similar, Whites seem to be affected more frequently 
than Blacks, Indians and Hispanics in the U.S.A.""·. Inflammatory bowel disease affects 
women and men similarly, but the incidence rates for CD are approximately 20 % higher in 
women, and for UC 20 % higher in men". 
People with higher socioeconomic status have a greater risk of developing IBn"'''. 
Environmental factors such as the use of oral contraceptives have also been associated Witll 
IBD21•24• Cigarette smoking seems to have a differentiated effect in IBD, it increases the 
risk for CD and protects against UC'·". 
The incidence of CD has shown a steady increase during the last decades in the 
western countries"''''''. The number of hospital admissions for CD in the Netherlands for 
instance has aimost doubled in the period from 1970 - 1977, whereas the admission rate for 
UC has hardly changed'·. For Sweden an increase and level-off at a relatively high 
incidence value has been described31 ,32,33,34, 
In UC, in contrast, the incidence rates have remained fairly constanr7,34,3S,36,37. 
The relation between incidence of UC and CD seems to be relatively constant at about 2: I". 
1.3 Etiology and pathogenesis 
As is the case for many other aspects of IBD the search for the cause of UC and CD 
has produced similarities between these diseases, the most important one being that the 
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etiology remains unknown for both. The epidemiology described in the previous paragraph 
suggests that both disorders are the result of a genetical susceptibility, immunological 
dysfunction and some environmental agent or agents. Research has mainly focused on 
genetics, pathology, infection, animal models, immunology and mediators of inflammation. 
Crohn's disease (CD) Ulcerative colitis (DC) 
Disease location All regions of Colon only gastrointsetinal tract 
Association with smoking Positive Negative 
Inflammatory response Transmural, Mucosal granulomatous 
Lymphokine profile 1 IL·2, IFN-y (Thl) I lL-4, lL-1O (Th2) 
lnununoglobulin profile IgG, IgG, 
Epithelial IgG and complement No Yes deposition 
Autoantibodies No Yes 
HLA haplotype DR-I, DQwS DR-2 
IL=Interleukin; IFN=Interferon; Thl-T Helper lymphocyte subset I. 
Table 1.2 Clinical, inununoiogic, and genetic differences between Crohn's disease and Ulcerative 
Colitis. 
1.3.1 Genetics 
Racial and ethnic differences in the prevalence of IBD have been reported by many 
authors"·20·". Another striking finding is the increased prevalence of IBD among first 
degree relatives of patients suffering from UC or CD'°·41.42. Twin studies are 
indispensable when studying the genetics of any disorder. The concordance found for 
monozygotic twins in comparison to dizygotic twins is a strong evidence for genetic 
susceptibility in IBD". 
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Research suggesting an association between F allotype of C3 (complement system) 
and CD of the small bowel" has been strengthened by studies of first degree relatives of CD 
patients, reporting an enhanced production of complement components by small intestine in 
these healthy individuals". These results could indicate that abnormal complement secretion 
may playa causative role in CD. These abnormalities were not found 
for UC, but Podolsky ef al." reported a selective deficiency in subclass IV mucin 
glycoproteins from UC patients. Mucin isolated from the colon of CD patients did not differ 
in subclasses from healthy controls. Results from Tysk and associates" confirm Podolsky's 
findings and suggest that this deficiency might be a primary mechanism, rendering an 
individual more susceptible to UC. 
The association of IBD with the HLA associated disorders ankylosing spodylitis and 
primary sclerosing cholangitis has prompted the idea that the HLA region may playa role in 
determining the severity of liD Multiple studies have reported an association of UC with 
HLA, although the results are not consistent over all studies". Especially the DR allele 
would appear to be a marker of disease susceptibility in certain ethnic groups". 
Studies at the beginning of this decade reported a subset of antineutrophil 
cytoplasmic antibodies (ANCA) to he an indirect marker of predisposition in UCO.51 • 
However, the presence of ANCA seems to be independent of the severity of the disease"'''. 
Even healthy relatives of UC patients have an increased frequency of positive ANCA 
compared to healthy controls54 • 
1.3.2 Immunology 
The immune system is a complex and indispensable defense system, and individuals 
with deficient immune responses die early in life, while those with a partially hampered 
immune system are at great risk of developing chronic illnesses. There is no doubt that the 
immune system plays a major role in the etiology of IBD Evidence for this view are the 
histopathological rmdings in both disorders, the laboratory rmdings and most convincing the 
effectiveness of immunosuppressive drugs in the treatment of IBD 
19 
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The mechanisms leading to clinical symptoms in IDD may be summarized as 
initiating events, being perpetuated in a genetically susceptible individual leading to tissue 
damage and eventually to clinical symptoms. 
Initiating events can range from any infectious agent to for instance drugs or toxic 
food additives. Drugs can directly influence the intestinal functions but can also exert their 
influence indirectly by changing the intestinal flora"·". 
Recent clinical and experimental observations have strongly suggested an important 
role for luminal products in the perpetuation of the inflammation. Decreasing exposure of 
the inflamed intestinal segments to microorganisms by surgical diversion or antibiotics 
usually diminishes the inflammation. Furthermore, in animal models of chronic 
inflammation the inflammation will not develop in a germ free enviromnent, while in some 
models bacterial products are used to generate the intestinal inflammation". 
The 'immunological' theories about the cause of IBD can be divided in two major 
categories". The first category assumes an inappropriate response of the patient's immune 
system to common agents. This abnormal reaction could be caused by a defect in the 
mucosal barrier or a defective regulation of the immune system. 
The second group of theories originates from the idea that the presence of a harmful 
agent in the intestinal lumen can cause alterations in the immune system leading to 
persistence of a specific infection. 
IBD, especially CD, is associated with an increased permeability of the mucosa 
caused by loss of the epithelial integrity, the local effects of inflammatory mediators and the 
transmigration of neutrophils"·". The increased permeability results in an overly active 
immune system by facilitating the absorption of toxic agents and antigens present in the 
lumen of the distal intestine". Several defects of the mucosal barrier have been postulated, 
such as changes in mucin structure, lectin binding and metabolism of short fatty acids"··'. In 
CD the increased mucosal permeability seems to be a genetically determined factor, 
rendering certain individuals susceptible for the disease. Indicative for this is the fact that a 
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proportion of the healthy relatives of CD patients also have an enhanced penneability of 
their mucosa after taking non-steroidal anti-inflammatory drugs"· ... 
The distal ileum and colon are the domain of many micro-organisms, antigens and 
all sorts of biological and chemical residues, capable of causing tissue damage. Nonnally 
the protective mechanisms of the intestines have no problem eliminating these potential 
dangers. In the case of actual damage to the intestinal surface the injuries are promptly 
repaired and the acute inflammatory responses effectively down-regulated". In IBD this 
immunoregulatory response may be inappropriate due to a genetic abnonnality. 
A defective immunoregulation may result in multiple abnonnal immune responses". 
One of these abnonnal reactions is an excessive aggressive response to elements in the 
intestinal lumen. 
The immune system is a very complex entity with many regulatory mechanisms such 
as immunoregulatory cells and mediators (pro- and anti-inflammatory). A disturbance of this 
balance in favour of the pro-inflammatory response, caused by an increase of pro-
inflanunatory mediators or a decrease of immunosuppressive molecules, may result in 
chronic inflammation. This suggests that IBD may be caused by a failure to down-regulate 
an acute, but in itself, common inflammatory response". The inflamed mucosa contains 
increased numbers of T lymphocytes, but the CD4+, CD8+ ratio does not differ 
significantly from nonnal mucosa". 
Dalton and associates reported an incapability of peripheral blood lymphocytes 
isolated from UC and CD patients to down-regulate the antigen stimulated proliferation of 
mononuclear cells". They also found that in contrast to intra-epithelial lymphocytes (I.E.L.) 
from control patients, I.E.L. from UC patients were unable to down-regulate the 
proliferative response of peripheral blood T cells to tetanus toxoid". 
Epithelial cells expressing HLA Class II molecules can present antigens to T cell,'·. 
Selby et al. examined the expression of HLA-DR and HLA-A, B, C antigens by colonic 
epithelium from IBD patients. They found an increased expression of HLA Class II antigens 
in inflamed colonic epithelium from CD as well as UC patients in comparison to non-
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inflamed epithelium". In UC and CD epithelial cells seem to stimulate CD4+ T cells, 
whereas enterocytes from normal tissue and non-IBD inflamed tissue predominantly 
stimulate CD8+ cells". These fmdings may indicate an intrinsic defect in epithelial celis 
from IBD patients, causing an up-regulation of the local immune response through 
activation of CD4 + cells and lack of stimulation of suppressor T cells. 
Another hypothesis to explain the cause of IBD is that of persistent infection as a 
result of a specific agent. For CD two infectious agents are currently receiving considerable 
attention, mycobacterium paratuberculosis and the measles virus. The first because of the 
striking resemblance to Johne's disease and ileocecal tuberculosis. Johne's disease is caused 
by M. paratuberculosis and is a chronic granulomatous enterocolitis occurring in ruminants. 
Furthermore, M. paratuberculosis has been cultured from patients with CD but not from 
patients suffering from UC or other gastrointestinal disorders". More recently, Sanderson 
and associates confirmed the presence of DNA specific for M. paratuberculosis in CD 
tissue, using PCR and Sweeney el al. suggested a possible mode of infection via cow 
milk 74.75. There are however, multiple pieces of evidence against the causative role of 
M. paratuberculosis in CD, such the lack of clinical efficacy of anti-mycobacterial 
antibiotics and the clinical benefit of corticosteroids. Other 'cons' are the non reproducible 
cellular and humoral immune responses and the absence of 'person to person 
transmission' 73. 
Evidence for persistence of measles virus in colonic tissue of CD patients has been 
reported". Together with the increased incidence of CD in individuals born during or just 
after measles epidemics", this has lead to the hypothesis that CD might be the result of a 
persistent measles viral infection. This hypothesis does not seem to be in accordance with 
the rising incidence for CD in spite of vaccination against the measles virus. Although 
vaccination is usually performed by using live measles vaccines, it is unlikely that infection 
with a wild-type virus would be associated with a lower risk than contact with the attenuated 
form of the virus. The virulence of the wild-type greatly exceeds that of the attenuated 
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viruses". For these reasons it seems unlikely that the measles virus would play an important 
role in the etiology of CD. 
Amplification of the immune response leads to tissue damage and eventually fibrosis. 
The early stage of the inflammatory process coincides with the production of the pro-
inflammatory cytokines tumor necrosis factor u (TNFu) and interleukin I (IL-l), primarily 
by activated macrophages. These cytokines not only activate immune cells such as T-cells, 
but they also stimulate mesenchymal, epithelial and endothelial cells"·80. In IDD there is an 
eobanced production of IL-l. Furthermore the IL-l concentrations in tissues correlate with 
disease activity". In rabbit immune complex colitis early administration of IL-l receptor 
antagonist (IL-1RA) diminishes the inflanunatory reaction in the colon". IL-lRA is a 
protein that inhibits binding of IL-l to its receptor and by doing so suppresses the pro-
inflammatory effects of IL-l. An imbalance between IL-l and IL-1RA, in favour of IL-l, 
would eobance T-cell stimulation and with this amplify the inflanunatory response". 
The IL-l induced T-cell stimulation eobances the release of interleukin 2 (IL-2) and 
interferon y (INFy) by Thl cells. In CD, in contrast to DC, IL-2 and INFy concentrations 
are increased. IL-2 and INFy induce cell mediated immunity, whereas the Th2 derived 
cytokine IL-IO, which is increased in DC, induces humoral immunity"·&5·". This could be 
interpreted as an activation of Thl cells in CD and Th2 cells in DC. 
The adherence of neutrophils, monocytes and T lymphocytes to blood vessels and 
consequently the migration into the inflamed tissue is preceded by expression of adhesion 
molecules and their ligands on these cells. IL-l, TNFu and INFy stimulate expression of 
these molecules80. This process of immigration is further stimulated by chemotactic 
molecules such as IL-8, transforming growth factor-p (TGFP), leukotriene B, and platelet 
activating factor, complement fragments and bacterial products. 
One of the most important complications of CD is obstruction of the intestinal lumen 
by stenosis. Stenosis is the result of fibrosis and hyperplasia of intestinal smooth muscle 
cells ". Both the proliferation of fibroblasts and of intestinal smooth muscle cells is 
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stimulated by IL-!, TNFa and insulin-like growth factor-! (IGF-I), produced by the 
inflamed tissue. Furthermore, !GF-! and TGFIl induce collagen synthesis. 
1.4 Current therapeutic approach 
1.4.1lntroduction 
Current medical treatment of ffiD largely still consists of corticosteroids and 
aminosalicylates. either alone or in combination. For patients who are intolerant or whose 
disease is refractory to these drugs there is an increasing variety of alternative drugs 
becoming available". Most of these drugs however, are still in an experimental phase, have 
limited applicability and are at best only suitable for specific groups of ffiD patients. 
Although glucocorticosteroids are the most important therapeutic agents in the 
management of lED they will not be discussed in this section. In Chapter 2 the clinical and 
pharmacological actions of glucocorticosteroids are discussed extensively. 
Recently clinical efficacy has been reported for nicotine in the treatment of uC". 
The second part of this thesis deals with immunopharmacological actions of this compound. 
In this section a brief overview of the aminosalicylates and some of the 
immunosuppressive drugs is given. 
1.4.2 Aminosalicylates 
The first arninosalicylate used in the treatment. of ffiD was sulphasalazine, 
sulphapyridine linked to 5-aminosalicylic acid (5-ASA) by an azo-bond. This molecule is 
split into its two compounds by bacteria in the colon"'. Subsequent research showed 5-ASA 
. to be the active therapeutic moiety of sulphasalazine, whereas the side effects seen during 
sulphasalazine therapy are predominantly induced by the sulphapyridine componenf'. 
5-ASA it thought to exert its effect locally in the intestinal mucosa. Although the exact 
mechanism of action is not known, it is evident that 5-ASA has multiple anti-inflammatory 
effects. Both, cyclooxygenase and 5-lipoxygenase pathways are inhibited by 5-ASA, 
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resulting in inhibition of eicosanoid production92.". Alternative anti-inflammatory 
mechanisms of 5-ASA are: prevention of lysosomal release and respiratory bursl", 
diminishing free radicals concentration" and inhibition of antibody synthesis". 
Aminosalicylates are the drug of choice for patients with mild to moderate UC or 
mild Crohn's ileitis" and adjuvant treatment for severe UC. In addition to its effectiveness 
in active disease, 5-ASA has also been shown to be effective in maintaining remission in 
UC". 
1.4.3 Methotrexate 
Methotrexate is the most widely used antimetabolite in cancer chemotherapy, but 
recently it has been used in the treatment of patients with IBD refractory to 
corticosteroids"'''''. It has immunosuppressive and anti-inflammatory properties, and in the 
treatment of IBD a steroid sparing effectlOl • Methotrexate is ineffective as maintenance 
therapy in lBO, especially in VCI.,.I03. 
1.4.4 Azathioprine I 6-mercaptopurine 
Both these drugs are competitive purine antagonists with strong immunosuppressive 
and anti-inflammatory effects",,·w5. Although their mode of action is not completely 
elucidated, it is clear that they inhibit the synthesis of DNA, RNA and protein. III vivo, 
azathioprine is converted into 6-mercaptopurine, which is the active metabolite. 
Azathioprine I 6-mercaptopurine have proven to be effective in UC as well as in CD, 
both in the induction and in the maintenance of remissiont06,to7,IQS,I09, In CD 
6-mercaptopurine does not only induce remission, but also causes closure of fistula 110, 
Furthermore, these drugs have a steroid sparing effect and could therefore have a role in 
limiting the severe side effects of long term steroid use. 
Both azathioprine and 6-mercaptopurine may require 3-6 months before displaying clinical 
efficacyIW.lIl. Although side effects limit the use of these immunosuppressive drugs they are 
generally moderate and only in about 10% patients necessitate cessation of therapy 106.109.111. 
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A frequently seen adverse effect is a dose related bone marrow depression, albeit usually of 
a reversible naturell2 . The increased incidence of various cancers seen in patients receiving 
azathioprine after organ transplant, does not seem to apply for IBD patients taking this 
drug'''. All in all, the long term use of azathioprine / 6-mercaptopurine can be considered 
relatively save, provided that regular haematological examination is being carried out. 
1.4_5 Cyclosporin 
Cyclosporin, also known as cyclosporin A, is an 11 amino acids containing cyclic 
polypeptide with powerful inununosuppressive actions. Its effects are predominantly the 
result of inhibition of an early step in the activation of T cells. This leads to blockage of the 
transcription of early genes encoding the cytokines'14. 
Cyclosporin, especially when administered intravenously, has a high clinical efficacy 
in severe UC as well as in severe CD'''. Lichtiger et al. treated II patients with severe UC 
who had failed to respond to high doses of intravenous corticosteroids with intravenous 
cyclosporin. All patients continued to receive 300 mg/day hydrocortisone intravenously and 
the aminosalicylic acid-based medications were continued in the patients using them at the 
start of the study. In this double blind, randomized, placebo controlled trial the response 
rate in the cyclosporin group was 82 % against a % in the placebo group (hydrocortisone ± 
5_ASA)1I6. 
Although trials with patients suffering from CD yielded less positive results 
cyclosporin is also effective in this disorde~". In contrast to 6-mercaptopurine, cyclosporin 
causes a rapid response. Patients improve clinically within two weeks after the onset of 
treatment. 
26 
Chapter 1 
1.5 Conclusions 
In Sununary, inflanunatory bowel disease is a chronic, relapsing inflanunation of the 
human gastrointestinal tract or part of it. Symptoms are variable as are the complications, 
allowing some patients a near to normal quality of life, while rendering others invalid. 
Although the etiology is still unknown medical treatment of inflammatory bowel disease has 
made progress during the last decade, albeit at an evolutionary rather than a revolutionary 
pace. 
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Corticosteroids 

Chapter 2 
Glucocorticoids 
2.1 Synthesis and metabolism 
Glucocorticoids (GC) are effective anti-inflanunatory agents which are notorious for 
the serious adverse effects they may cause when administered in a too high dose or over an 
extended period of time. Nevertheless, they are physiological hormones secreted by the 
zona fasciculata of the adrenal cortex and life would be impossible without them'. 
Corticosteroids are synthesised from cholesterol, derived from plasmalipoproteins. First, 
cholesterol is converted into pregnenolone'. This occurs in the mitochondria and is 
stimulated by adrenocorticotrophic hormone (ACTH). Following this step, the synthesis 
pathway branches into two routes: one passes through 17-C(-hydroxyprogesterone and 
I-deoxycortisol to cortisol, while the other proceeds from 17-progesterone and 
corticosterone to aldosterone. These two different end products also differ in function. This 
cascade of stimulary events is inhibited by cortisol. Thus, cortisol regulates its own release'. 
The glucocorticoids of which cortisol is the main exponent ill vivo, play an essential role in 
coping with stress4 . 
The other group of steroids produced by the adrenal cortex are termed 
minaralocorticoids and are responsible for regulation of the salt and water metabolism. The 
main mineralocorticoid is aldosterone2 . As with most classifications, the division in 
glucocorticoids and mineralocorticoids is artificial and arbitrary, because naturally 
occurring GC also possess mineralocorticoid activity and vice versa. 
Metabolism 
Cortisol is predominantly metabolized in the liver and the plasma half-life is 
approximately 100 minutes. Metabolism by the liver results in a decrease biological activity 
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and increases the water solubility of the metabolized hormones'. The latter is necessary in 
order to enable excretion by the kidney. 
+ Sensory inpul, 
s"." ~~~ 
Intarlaukln·1, 
Tumor Necrosis Faclor 
(Cacheclin) 
t+ 
A"" ... d M'''~ - - + 
Proslaglandins, 
aminas, 
and? 
& "he.'Ph'~~ CO",,,, -O\li!lI~.9:l!mll!!i~:lJ' Adlenal COllex (Hydrocortisone) -Accessory Cells 
Zona fasc!culala 
Figure 2.1 Schematic representation of endogenous glucocorticoid production. 
2.2 Physiological effects of glucocorticoids 
The name glucocorticoids originates from the influence these hormones have on 
glucose metabolism. However, the physiological effects of these hormones extend far 
beyond carbohydrate metabolism. Glucocorticoids play an important role in lipid and 
protein metabolism, regulate the immune system and renal function, and have a strong 
influence on growth, development, bone metabolism and central nervous system activity'. 
In view of the topic of this thesis, inflammatory bowel disease, the 
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immunoregulatory actions of GC will be discussed in more detail. 
Carbohydrate, protein and lipid metabolism 
Glucocorticoids stimulate gluconeogenesis, resulting in increased blood glucose and 
liver glycogen levels. Underlying this process is the inhibition of protein synthesis by GC, 
which causes a transfer of amino acids from muscle, fat tissue and bone to the livef·7.'. In 
the liver amino acids are converted to glucose. Furthermore, GC stimulate the catabolism of 
lipids in adipose tissue and enhance the action of other lipolytic agents. The result is an 
increased plasma free fatty acid level'. Thus, the effects of GC on glucose metabolism are 
opposite to those of insulin6,7,1O,1l.12. 
Immune and anti-inflammatory responses 
In contrast to the immunosuppressive and anti-inflammatory actions of GC in 
therapeutic doses, our knowledge about the role of physiological levels of GC in 
immunological and inflammatory responses is limited. The fact that surgical removal of the 
adrenal gland greatly exacerbates the inflammatory responses, strongly suggests an anti-
inflammatory role for GC under physiological circumstances. 
The endogenous GC level in the circulation varies strongly". Inflammation is 
characterized by release of numerous inflammatory mediators by inflammatory cells such as 
interleukin 1 (lL-l) and tumor necrosis factor a (TNFa). These mediators will indirectly 
activate the hypothalamic-pituitary-adrenal axis by stimulating certain centres in the brain. 
The result is enhancement of cortisol release, leading to inhibition of the inflammatory 
reactionI4,15, 16, 11, 18. 
The difference in susceptibility to streptococcal cell wall-induced arthritis between 
Lewis rats and Fisher rats further illustrates the role GC play in preventing the activated 
defence mechanisms from overshooting"·'o. The extremely susceptible Lewis rats have 
impaired plasma ACTH and GC responses to the administration of IL-l and corticotropin 
releasing hormone (CRR). The cause of these inadequate responses is a defective regulation 
41 
Glucocorticoids 
of the CRH gene in the paraventricular nucleus'°. These observations have been further 
strengthened by data from experiments with RU 486, a glucocorticoid receptor antagonist. 
Treatment of Fisher rats with RU 486 increases their susceptibility to the induction of 
arthritis. 
2.3 Mechanism of action 
G1ucocorticoids exert their actions after binding to specific receptors. These 
receptors are not located in the cell membrane but within the cytoplasm, at least in the 
absence of the steroid. The glucocorticoid receptor (GR) belongs to a supergene family 
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Figure 2.2 Classic model of glucocorticoid action. Glucocorticoid (GCS) enters the cell 
and binds to a cytoplasmic GR that is complexed with two molecules of a 90 kd heat 
shock protein (hsp 90). OR translocates to the nucleus where, as a dimer, it binds to a 
ORE on the S'-upstream promoter sequence of steroid-responsive genes, OREs may 
increase transcription, and nGREs may decrease transcription, resulting in increased or 
decreased mRNA and protein synthesis. 
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containing cytosolic receptors for various steroids, such as progesterone and oestrogen, and 
for thyroid honnone, retinoic acid and vitamin D'I.". The GR is a heteromer consisting of a 
steroid- and a DNA-binding subunit and two 90 kD heat-shock proteins". Following 
binding of the GC to its receptor the activated receptor complex moves to the nucleus of the 
target cell. In the nucleus this complex binds to the glucocorticoid response elements, 
fonned by specific DNA sequences. This results in the down-regulation of the transcription 
of pro-inflammatory genes and up-regulation of the transcription of anti-inflammatory genes 
such as lipocortin, neutral endopeptidase and inhibitors of plasminogen activator. 
Glucocorticoids may also modulate gene transcription by destabilizing specific messenger 
RNA molecules". 
Genes down-regulated by GC 
IL-l, IL-6, IL-8 
TNFa, IFNy, GM-CSF 
Cyclooxygenase type II 
Nitric oxide synthase 
Elastase 
Plasminogen activator 
Collagenase 
Genes up-regulated by GC 
Lipocortin 
Neutral endopeptidase 
Receptors for cytokine 
Receptors for honnones 
Plasminogen activator inhibitor 
Table 2.1 Gene Modulating actions of glucocorticoids. 
2.4 III vivo anti-inflammatory effects of glucocorticoids 
Effects 011 illjlamlllatory cells 
Glucocorticoid administration not only alters the number of leucocytes but also 
affects the functions of inflammatory cells. They inhibit cytokine release by both 
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lymphocytes and monocytes, proliferation of lymphocytes and release of arachidonic acid 
metabolites by monocytes and macrophages"·"·27., .. Granulocyte functions, on the other 
hand, are less influenced by GC. Chemotaxis, phagocytosis and release of arachidonic acid 
metabolites by neutrophils are not inhibited by GC, nor is chemotaxis by eosinophil;""". 
Although data from in vitro studies suggest that GC do not inhibit chemotaxis or 
adherence to endothelial cells, in vivo studies have suggested an inhibition of 
transendothelial migration of leucocytes. Biopsies obtained from the airways of 
glucocorticoid-treated asthmatic patients exhibit a reduced number of lymphocytes and 
eosinophils". There is still a lot to be unravelled about the mechanism through which GC 
reduce the infiltration of inflammatory cells to the inflamed tissue. However, recent ill vitro 
studies have shown that cytokines such as IL-J, IL-4 and TNFa activate the endothelium, 
increasing its adhesive properties and by doing so, stimulate the adherence of leucocytes and 
their subsequent migration". Animals and human studies have demonstrated inhibition of 
cytokine release by GC"·J.l·35.", suggesting suppression of endothelial activation. A key 
factor in the migration of leucocytes are the chemoattractants such as lipid mediators, 
peptides and chemokines. Glucocorticoids strongly inhibit the production of these 
chemotactic factors. 
Vascular effecls of glucoconicoids 
Two important aspects of inflammation are increased blood flow and permeability. 
Both facilitate the transport of leucocytes and plasma proteins to the inflammation sites. A 
number of inflammatory mediators cause the blood vessel diameter and the permeability to 
increase. Glucocorticoids inhibit the release of these mediators such as IL-J, TNFa, 
neuropeptides, nitric oxide and prostaglandins. The inhibition of vascular permeability and 
diameter by GC, however, is not only a result of this indirect action but also of the direct 
influence of GC on endothelial cell shape and contractility"''''''. 
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2.5 Glucocorticoids in inflammatory bowel disease 
PI/anl/acokinelics 
As with any disease affecting the intestines one should be aware of the potential risk 
of impaired absorption when treating inflammatory bowel disease patients with oral Gc. 
Plasma concentrations vary considerably after oral ingestion of the same dose of GC by 
normal subjects or patients with mD"'. It is still unclear whether absorption of oral GC in 
mD patients is nonnal or not. Both, an impaired absorption of prednisolone'I.", especially 
in the case of extensive small bowel Crohn's disease", as well as a nonnal absorption have 
been described in mD patients .. ,45,46 in comparison to healthy controls, 
2.5.1 Ulcerative colitis (DC) 
As early as in the forties data from uncontrolled studies with GC and ACTH 
suggested a beneficial effect of these compounds in the treatment of Uc'7,48,49,SQ,51,52.53. 
Subsequently, the efficacy of GC as therapy for UC was clearly demonstrated by placebo-
controlled studies"''', Although some studies showed ACTH to have a slightly better result 
than GC in the UC patients treated for relapse, it is nowadays hardly ever use<f6.". The 
disadvantages of ACTH are the high costs and the fact that it has to be administered 
parenterally. 
For mild to moderate inflammation the optimal dose was found to be 40-60 mg of 
prednisolone daily". Although the use of enemas has enabled the employment of local 
therapy it has not been able to eliminate the side effects of treatment with GC entirely. This 
is due to the fact that even with local application of hydrocortisone hernisuccinate or 
prednisolone 21 phosphate, a considerable amount of the GC is absorbe<f,,60·61.62,". 
Although GC are the most effective drug in the treatment of acute exacerbations of 
ulcerative colitis, they do not reduce the rate of relapses'6,,,,.,. 
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2.5.2 Crohn's disease (CD) 
Placebo-controlled trials with GC for the treatment of CD were done much later than 
those for UC. As is the case for UC. treatment with GC is effective in acute exacerbations 
of CD 66.67. In CD. however, low dose GC therapy seems also to reduce the rate of relapses 
in CD patients brought into remission with Gc"'·67.68.". 
2.6 Conclusions 
Glucocorticoids are the clinically most effective treatment for ffiD available today. 
However. their influence is not confmed to the intestines. Glucocorticoids affect almost 
every part of the intmune system and multiple other systems. Prolonged treatment with GC 
can therefore cause various side effects. In order to reduce these side effects more and more 
emphasis is being placed on research efforts to develop rapidly metabolized topical steroids. 
Further research concerning the anti-inflammatory effects of GC is warranted 
because this might enable us to detemtine wbich of these effects are necessary to induce 
remission in ffiD. Such knowledge will render the tools for the development of new anti-
inflammatory compounds with the selectivity yearned for. 
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Chapter 3 
Inhibition of the production of mediators of inflammation by 
corticosteroids is a glucocorticoid receptor-mediated process' 
Abstract - In order to find an explanation for corticosteroid resistance we assessed 
whether inhibition by dexamethason (DEX) of the stimulated production of TNFa, 
IL6, PGE, and LTB, by peripheral blood mononuclear cells (MNC) depends on 
binding to the glucocorticoid receptor (GR) and whether it is determined by the 
number or the affinity of the GR of these cells. GR number and affinity of MNC 
were determined by means of a whole cell DEX binding assay. MNC were incubated 
with DEX and LPS or A23187 in the absence or presence of RU486, a potent steroid 
antagonist. DEX caused a concentration dependent inhibition of TNFa, II. and 
PGE, production but had no effect on LTB, production. RU486 significantly blocked 
the effect of DEX, but no correlations were found between the inhibition of mediator 
release and the K" or receptor number. 
3.1 Introduction 
Corticosteroids decrease the severity of the inflammation and cause a subjective 
improvement in the majority, but not in all patients with non-infectious inflammatory 
disorders such as inflammatory bowel disease (IBD)\ asthma' and rheumatoid arthritis'. 
The anti-inflammatory effects of corticosteroids are ascribed to inhibition of the production 
of mediators of inflammation, including eicosanoids and cytokines'·'·6. 
'Based 011: Madretsma G.S., van Dijk A.P.M., Tak C.J.A.M., Wilson J.H.P., 
Zijlstra F.J. Inhibition of the production of mediators of inflammation by corticosteroids is a 
glucocorticoid receptor-mediated process. Mediators of illflammation. 1996;5: 100-103 
53 
Inhibition oj the production oj mediators of inflammatioll ..... 
Several control studies have shown that topical or systemic corticosteroids are much 
more effective than placebo controls, but that not all patients improve. Depending on the 
dose and route of application, duration of the treatment, severity of the exacerbation and the 
parameters under investigation, approximately 10 - 40 % of the patients do not respond or 
respond insufficiently to corticosteroids"'. 
Stimulation of mononuclear cells (MNC) by lipopolysaccharide (LPS) or Ca-
ionophore enhances the production of a range of infianunatory mediators by these cells such 
as the cytokines tumor necrosis factor a (TNPa) and interleukin 6 (IL-6), and the 
eicosanoids prostaglandin E, (pGE,) and leukotriene B, (LTB,)9. This provides an in vitro 
model for studying the anti-inflanunatory properties of corticosteroids. 
In order to clarify some aspects of the mechanism through which corticosteroids 
exert their anti-inflarnmatory effects we examined the effect of dexamethasone on the 
production of mediators of inflammation by human MNC ill vitro and assessed whether this 
effect depends on binding of corticosteroids to the glucocorticoid receptor (GR). 
The hypothesis of this study was that the inhibition of the production of mediators of 
inflanunation by corticosteroids is a glucocorticoid receptor-mediated process. We 
furthermore tested if the ability of dexamethasone (DEX) to inhibit the LPS-stimulated 
production of TNPa, IL-6, PGE, and the Ca'+-ionophore enhanced LTB, production by 
MNC is determined by the number or affinity of glucocorticoid receptors (GR) on these 
cells. 
3.2 Materials and Methods 
Healthy volunteers 
Approval for this study was obtained from the Medical Ethical Committee of the 
University Hospital Rotterdam. 
Venous blood was obtained from 9 healthy adults, ranging in age from 22 to 37 
years, who joined voluntarily after full explanation of the nature, significance and scope of 
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the study. None of the subjects had taken corticosteroids or any other anti-inflammatory 
drug for a period of at least 4 weeks prior to donating blood. 
Isolation of human MNC 
Mononuclear cells were isolated from the heparinized venous blood immediately 
after blood sampling. The method used was a modification of the technique origioally 
described by BOyum". Briefly, the blood was diluted 1:1 with phosphate buffered saline 
(pBS: Oxoid, U.K.) before fractioning it by an one-step Ficoll-paque gradient (pharmacia, 
Sweden) centrifugation at lIOOxG for 15 mioutes at 20° C. The interphase was washed in 
PBS and resuspended in Dulbecco's Modified Eagles Medium (DMEM) containing HEPES 
and foetal calf serum (Gibco, UK), supplemented with penicillin and streptomycin (Flow 
Lab, UK). Cells were stained by Hemacolor (Merck, Germany), the final yield of MNC 
was greater than 95 % and the cell viability (tested by Trypan blue exclusion) was over 
97 %. 
Culturing of MNC and measurement of cytokines and eicosanoids 
The cells (2xl0' per well) were cultured io DMEM and incubated in the presence or 
absence of varying concentrations of DEX (Geofarma, The Netherlands) for 24 hours prior 
to stimulation with LPS (5 I'g/ml, E. coli 01Il:B4, Sigma, USA) for 24 hours or 01+-
ionophore (A23187, 1 I'M, Sigma, U.S.A.) for 15 mioutes. All iocubations were performed 
at 37°C in an humidified atmosphere of 5 % Co, and 95 % air. DEX was dissolved io 
culture medium and concentration of DEX varied from Hr' to 10" M. 
TNFa and IL-6 were measured by commercially available ELISA-kits (Central 
Laboratory for Bloodtransfusion, The Netherlands) whereas PGE, and LTB, levels were 
determined by specific radioimmunoassays (Standards: Sigma U.S.A., 'H-Iabels: Amersham 
UK and antibodies: Advanced Magnetics Inc., USA). 
The effects of different concentrations of DEX on secretion of TNFa, IL-6 and 
PGE, were expressed as percentage inbibition of production io control cultures ( cells 
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incubated with DMEM plus supplements and LPS ). 
Assessment of glucoconicoid receptor number by a whole cell assay 
The method used was that described by Lamberts et al.", but a lOoo-fold excess of 
unlabelled RU-486 (Roussel, France), a corticoid receptor antagonist, was used instead of 
an excess of unlabelled DEX. A stock solution was made by dissolving RU-486 in ethanol. 
This solution was diluted in culture medium. Final concentration ethanol in the assay 
samples was less than 0.1 % . 
In order to enhance the dissociation of endogenously bound corticoids, the MNC 
used in the assay were washed 3 times in DMEM, each time allowing for an equilibration 
period of 30 min at 37" C in a shaking waterbath12 • 
Specific binding was determined by subtracting the amount of nonspecifically bound 
radioligand from the total amount bound. Data were analyzed by constructing a Scatchard 
plot". 
Statistics 
The effect of DEX on the stimulated release of each mediator was studied in 9 
separate experiments, with blood from 9 different donors. Values are expressed as mean ± 
S.E.M. Control and DEX-treated cell cultures were compared by paired t-test. P-values 
< 0.05 were considered significant. 
Effect of DEX alone versus the effect of DEX after preincubation with RU486 was 
compared by Manova. 
3.3 Results 
Mediator production by MNC 
After the incubation period LPS-stimulated MNC released the mediators measured in 
the following concentration, TNFct: 90 ± 25 pg/Ht cells, IL-6: 1165 ± 320 pg/Ht cells, 
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PGE,: 1420 ± 340 pg/lO'. MNC stimulated with Ca2+ -ionophore released: 2970 ± 940 pg 
LTB/lO' cells. 
Effect of DEX on mediator release by MNC 
The inhibitory effect of DEX on TNF<t production was of comparable magnitude to 
that of IL-6 and PGE" with an IC so value (concentration of DEX that causes a 50 % 
decrease in mediator release) of 65 nM in comparison to 145 and 140 nM for IL-6 and 
PGE, respectively. There was a considerable inter-individual variation in le,o values in 
response to DEX with a 95 % confidence interval of [10 - 400 nM] for TNF<t, [15 - 1095 
nM] for IL-6 and [30 - 690 nM] for PGE,. The effects of DEX on the production of the 
studied mediators are shown in figure 3.1. 
DEX had no effect on Ca2+-ionophore-stimulated LTB, release. 
Antagonism of tlte effects of DEX in MNC by RU486 
Incubation of MNC with RU486, a steroid receptor antagonist, for 2 hours prior to 
the addition of DEX diminished the inhibitory effect of the glucocorticoid in a dose 
dependent manner (figure 3.2). 
Assessment of glucocorticoid receptor Ilumber and K.t in MNC 
Glucocorticoid receptor content was 4430 ± 340 sites I cell (mean ± S.E.M.) and 
the K., 9.5 ± 0.7 nM. In figure 3.3 a representative Scatchard plot from one experiment of 
the binding of 'H-DEX to glucocorticoid receptors of MNC is shown. The slope is equal to 
the negative reciprocal of the dissociation constant (-llK,,), and the intercept on the abscissa 
equal to the total concentration of receptors (B=,). 
No correlations were found between the inhibition of mediator release and K; or 
receptor number. 
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and (b) PGE, (0) and LTB, (0) by MNC cultures stimulated by LPS 
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9 experiments perfonned on MNC from 9 different donors. * Significance 
with P< 0.05 compared to LPS-enhanced production. 
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Figure 3,2 Effect of DEX on the secretion of (a) TNFa (0), (b) IL-6 (V) 
and (c) POE, (0) and the effect of DEX after preincubation of MNC with 
RU486 10·' M (0) or 10' M (II). RU486 significantly inhibits the effect of 
DEX in a dose dependent fashion, P < 0.001. 
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Figure 3.3 Scatchard plot of specifically bound 3H-dexamethasone to MNC. 
MNC were incubated with 0 - 16 oM lH-dexamethasone in the absence or 
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case shown are 12.8 oM and 15.7 fmol/106 MNC respectively. 
3.4 Discussion 
The inhibitory effect of DEX in this ill vitro experiment varied considerably from 
donor to donor. The effect of DEX on the release of TNFa, IL-6 and PGE, can not be 
explained by DEX's effect on the viability of the cells, otherwise the same effects should 
have been found for LTB, release. Instead, no significant differences were found between 
LTB, production in the presence versus absence of DEX. This might indicate that 
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corticosteroids do not inhibit 5-lipoxygenase in MNC as they do the gene expression of 
cytokine-induced cycloxygenase 2 in monocytes1'. Furthermore, culture of MNC with 
DEX, in the concentrations used in this study, did not effect the viability of these cells as 
detetrnined by trypan blue exclusion. 
The fact that the effect of DEX could be diminished or even abolished by pre-
incubation of the MNC with RU486, a steroid receptor antagonist, strongly suggests a 
glucocorticoid receptor mediated process. 
Mononuclear cells play a central role in chronic inflammation. They possess the 
capacity to produce eicosanoids and cytokines which modulate the inflammatory 
responselS.16.17. Corticosteroids exert their anti-inflanunatory effects partly by inhibiting the 
production of inflammatory mediators, through a glucocorticoid receptor-mediated process. 
This means that the GR plays a crucial role in the anti-inflammatory effects of 
corticosteroids. 
Considering these frudings it seems logical tIlat inter-individual variations in reaction 
to corticosteroids could be explained by variation in the number of GR on the MNC or the 
affinity of these receptors for DEX. No correlations were found however, between rc,o of 
the mediators under investigation and receptor number or K". Thus, the degree of response 
of MNC of healthy donors to DEX does not seem to be determined by the characteristics of 
the GR, and other factors must playa role. This finding however does not exclude the 
possibility that changes in GR number or affinity are important in glucocorticoid resistance 
in inflammatory diseases. 
The MNC used in this study were isolated from blood obtained from healthy 
volunteers, who presumably have a normal response to corticosteroids. It is to be expected 
that comparison of MNC obtained from patients who have proven to be non-responders to 
corticosteroids with MNC of responders may reveal differences in GR characteristics more 
clearly. Studies with MNC isolated from blood obtained from inflanunatory bowel disease 
patients responding to corticosteroids and patients not responding have been initiated. 
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Glucocorticoid resistance in inflammatory bowel dlsease' 
A glucocorticosteroid receptor-mediated disorder? 
Abstract - A minority of patients with inflammatory bowel disease (IBD) do not 
respond to high doses of glucocorticosteroids. Variation in response to 
corticosteroids could be due to variation in number or affrnity of glucocorticoid 
receptors (GR) on mononuclear cells (MNC). In order to test this hypothesis we 
assessed if GR-number and GR-affinity of MNC isolated from venous blood of 
IBD-patients not responding to corticosteroid therapy differ from those of healthy 
volunteers and IBD-patients who do respond to this type of therapy. GR-content and 
Kd for the three groups were respectively, healthy volunteers: 4430 ± 340 sites per 
cell and 9.5 ± 0.7 nmolll; responders: 3900 ± 210 sites/cell, 7.9 ± 0.6 nmolll; 
non-responders: 2450 ± 310 sites/cell, 6.0 ± 1.4 nmolll (difference non-responders 
versus responders and healtllY volunteers, P < 0.01). Thus, mononuclear cells of 
IBD-patients not responding to glucocorticosteroids have a low glucocorticoid 
receptor number. 
However, experiments with blood drown from the same nonresponders 9 to 12 
months later did not confirm this finding. A possible explanation for this discrepancy 
could be that corticosteroid resistance in IBD is acquired and reversible, as seems to 
be the case in asthma. 
'Based on: G. Stanley Madretsma MD, Jeanette P.M. van Dijk BSc, J.H. Paul 
Wilson MD, Ruud Schouten MD, Dirk-Jan Bac MD, Freek J. Zijlstra PhD. Submitted. 
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4.1 Introduction 
Corticosteroids decrease the severity of the inflammation and give a subjective 
improvement in the majority, but not in all patients with inflammatory bowel disease (lED). 
Depending on the dose and route of application, duration of the treatment, severity of the 
exacerbation and the parameters under investigation, approximately 10 - 40 % of the 
patients do not respond or respond insufficiently to corticosteroids!", 
There are several possible reasons for lack of clinical response to corticosteroids, 
Individual differences in pharmacokinetics of corticosteroids occur, which can explain part 
of the variations in responses"', It should be pointed out, however, tllat two small studies 
failed to demonstrate diminished absorption after oral administration in lBo"', In some 
patients non-compliance may be the cause of lack of response', Some individuals however, 
may be poor responders at a cellular level. 
Individual differences in the effects of corticosteroids on mononuclear cells have 
been found"', Corrigan et aI.' showed that there is a correlation between ill vitro inhibition 
of phytohemagglutinin-induced proliferation of T-Iymphocytes by dexamethasone and the 
clinical response to corticosteroids in asthmatic patients, This finding suggests that it might 
be possible to identify non-responders before starting treatment by using ill vitro tests, The 
anti-inflammatory effects of corticosteroids are ascribed to inhibition of the production of 
mediators of .inflanunation, including eicosanoids and cytokines. Previous studies in our 
laboratory showed this inhibition to be glucocorticoid receptor mediated", Interindividual 
variation in reaction to corticosteroids in IBD therefore could be explained by variation in 
the number of glucocorticoid receptors on the MNC or the affmity of these receptors for 
corticosteroids, In order to test this hypothesis we assessed if patients who had failed to 
react to corticosteroid therapy have less GR on their mononuclear cells, 
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4.2 Methods 
Approval for this study was obtained from the Medical Etllical Committee of the 
University Hospital of Rotterdam. 
Venous blood was obtained from three groups of individuals. The first group 
consisted of 9 healthy adults, ranging in age from 22 to 37 years (Controls). The second 
group were 6 lED-patients (age: 27 to 66 years) who had undergone colectomy because the 
inflammation failed to react to medical treatment, even with high doses of corticosteroids 
(Non-responders). 'High doses of corticosteroids' was defmed as 60 mg prednisone Or more 
per day for at least 5 consecutive days. The third group comprised 6 lED-patients (age: 21 
to 59 years) with a history of one or more exacerbations which had responded successfully 
to corticosteroids (Responders). 
All of these responding patients had at least one exacerbation rated as moderate to 
severe by endoscopic examination. All individuals participated after full explanation of the 
nature, significance and scope of the study. None of the subjects had taken corticosteroids 
for a period of at least 4 weeks prior to donating blood. 
lso/atioll of hlllllall mOI/Ollllclear cells 
Mononuclear cells were isolated from the heparinized venous blood inuuediately 
after blood sampling. The method used was a modification of the technique described by 
Boyum". Briefly, the blood was diluted 1:1 with Phosphate Buffered Saline (pBS; Oxoid, 
U.K.) before fractioning it by a one-step Ficoll-paque gradient (Pharmacia,Sweden) 
centrifugation at 2500 rpm for 15 minutes at 20' C. The interphase was washed in PBS and 
resuspended in Dulbecco's Modified Eagles Medium (DMEM) containing Hepes and foetal 
calf serum (Gibco, UK), supplemented with penicillin and streptomycin (Flow Lab, UK). 
Cells were stained by Hemacolor (Merck, Germany), the final yield of MNC was greater 
than 95 % and the cell viability (assessed by Trypan blue exclusion) was over 97 %. 
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Assessmelll oj glucocorticoid receptor lIumber by a whole cell assay 
The method used was that described by Lamberts et al.", but a 1000-fold excess of 
unlabelled RU-486 (Roussel, France), a corticoid receptor antagonist, was used instead of 
an excess of unlabelled dexamethasone. A stock solution was made by dissolving RU-486 in 
ethanol. This solution was diluted in culture medium, resulting in final concentration 
ethanol in the assay samples of less than 0.1 % . 
In order to enhance the dissociation of endogenously bound corticoids, the 
mononuclear cells used in the assay were washed 3 times in culture medium, each time 
allowing for an equilibration period of30 min at 37' C in a shaking water bath". 
Specific binding was determined by subtracting the amount of nonspecifically bound 
radioligand from the total amount bound. Data were analyzed by constructing a Scatchard 
plot". 
Plasma cortisol level 
An aliquot of the heparinized blood was centrifuged at 4000 rpm for 10 min at 25 'c 
and the plasma stored at -80 'C until measurement of the cortisol level by radio immuno 
assay (Coat-a·count cortisol; Diagnostic Products Corporation, The Netherlands). 
Statistics 
The corticosteroid receptor number, K., and plasma cortisol levels are expressed as 
mean ± S.E.M. The Mann-Whitney U test was used to compare results in the three groups. 
A P value < 0.05 was considered significant for each comparison. 
4.3 Results 
Assessment oj glucocorticoid receptor lIumber and KJ ill mononuclear cells. 
In figure 4.1 a representative Scatchard plot from one experiment of the binding of 
'H-dexamethasone to glucocorticoid receptors on mononuclear cells is shown. The slope is 
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Figure 4.1 Scatchard plot of specifically bound 3H-dexamethasone to 
mononuclear cells. MNC were incubated with 0 - 16 nmoltl 3H_ 
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unlabelled RU-486. K.! and BII'-u in the case shown are 12.8 nmoltl and 15.7 
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Chapler 4 
equal to the negative reciprocal of the dissociation constant (-1/1(,,), and the intercept on the 
abscissa equal to the total concentration of receptors (B~,). 
The glucocorticoid receptor content for the healthy volunteers was 4430 ± 340 
sites/cell (mean ± S.B.M.) with a I(" of 9.5 ± 0.7 nmol/1. For the responders we 
calculated 3900 ± 210 sites /cell, with a I(" of 7.9 ± 0.6 nmolll , whereas the non-
responders had 2450 ± 310 GR per cell, with a I(" of 6.0 ± 1.4 nmoll1. 
69 
Glucoconicoid resistance ;11 illjlammaJory bowel disease. 
70 
a 
b 
C 
'i 
\t 4000 
~ 
n 
~ 3000 
~ 
c 2000 
t 
3 1000 
#. 
o L----'-_----'_ 
~ 
E 
oS 
" 
4 
" 
2 
0 
~ 800 
E 
oS 
'i 600 
• 1 
'0 400 
i 200 0 
0 
o control 
• responders 
III non-responders 
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The mononuclear cells of the non-responders had a significantly lower 
glucocorticoid receptor number (figure 4.2a), compared to the two other groups (P< 0.01). 
The GR content on MNC of the responders did not differ significantly from that of the 
healthy volunteers. No significant differences were observed in the I\, of the GR between 
the three groups (figure 4.2b). 
Plasma cortisol level 
The measurements of cortisol in plasma are shown in figure 4.2c. Mean cortisol 
level in healthy volunteers was 390 ± 95 nmolll. This did not differ significantly from the 
plasma cortisol levels measured for the responders 435 ± 110 nmolll and non-responders: 
395 ± 70 nmolll (figure 4.2c). 
4,4 Discussion 
This study shows that the majority of patients who have not responded to high dose 
of corticosteroids for IBD have a reduced numher of corticosteroid receptors on their 
mononuclear cells. The ability to recognise IBD-patients who will not respond adequately to 
treatment with corticosteroids, before starting treatment, is of potential value, as these 
patients could then be given alternative immunosuppressive drugs at an early stage. The 
criteria used in this study to classify glucocorticoid resistance are rigorous, but gave us a 
clear and objective tool to discriminate hetween responders and non-responders to 
glucocorticoid therapy. 
A 'washout' period of at least 4 weeks was chosen because of the fact that patients 
taking glucocorticosteroids experience a phenomenon known as 'receptor down regulation'. 
This means that the number of GR on the cells of these individuals decreases during 
treatment with glucocorticosteroids. Receptor down regulation occurs within 24 hours, but 
is a reversible process. After cessation of glucocorticoid administration the number of GR 
gradually returns to normal". 
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In addition to these two groups of patients there are also patients who respond only 
to high dose of glucocorticosteroids. We chose to only include the patients from both 
extremes of the spectrum of corticosteroid response because comparison between these two 
groups was likely to display the differences more clearly. 
Mononuclear cells play a central role in chronic inflammation. They have the 
capacity to produce eicosanoids (biological active lipids) and cytokines (immuno regulatory 
proteins) which modulate the inflammatory response"·I6·I7. Glucocorticosteroids exerts their 
anti-inflammatory effects partly by inhibiting the production of these inflammatory 
mediators, through a glucocorticoid receptor-mediated process. This means that the GR 
plays a crucial role in the anti-inflarmnatory effects of glucocorticoids. A possible 
explanation for the phenomenon of corticosteroid resistance in IBD therefore could be 
altered glucocorticoid receptor characteristics, e.g. an aIteration of GR-number or affInity. 
As far as we know no research has been published on GR srudies of MNC of 
glucocorticoid resistant IBD-patients. In asthmatics who do not respond to aerosol or 
systemic corticosteroids, in vitro reduction in monocyte function has been described, and 
also a change in glucocorticoid receptor affinity for dexamethasone"'''. A reduction in 
glucocorticoid receptor number has not been reported. Recently, reports have been 
published describing familial cortisol resistance"·20 in which a reduced glucocorticoid 
receptor number and elevated blood cortisol levels were found in some of these patients. 
The authors concluded that familial cortisol resistance might be caused by a lower 
glucocorticoid receptor number. 
In our patients mononuclear cells from non-responders have a signifIcant lower 
GR-number in comparison to responders and healthy volunteers, whereas the affinity of 
these receptors for dexamethasone do not differ. This indicates the absence of a 
compensation mechanism in these cells, lowering the K" in order to compensate the decrease 
in receptor number by an increase of the affinity of the receptors for glucocorticoids. A 50 
% reduction in glucocorticoid receptor number, even without a change in receptor affinity is 
sufficient to change effectiveness of glucocorticoids as shown by Pepin el ai, who found that 
72 
Chapter 4 
a decrease in GR-number of about 50 % causes symptoms in transgenic mice bearing 
antisense RNA transgene21 . 
In contrast to some forms of familial cortisol resistance the mean blood cortisol 
levels of the non-responders did not differ significantly from that of the responders or 
healthy volunteers. Further studies have been initiated to characterize the nature of the 
defect in our patients. 
However, experiments with blood drown from the sarne nonresponders 9 to 12 
months later did not confirm this rmding. A possible explanation for this discrepancy could 
be that corticosteroid resistance in IDD is acquired and reversible, as seems to be the case in 
asthma22,23, 
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PART 3 
Smoking and Nicotine 

Chapter 5 
Pharmacology and Immunology 
5.1 Introduction 
Although the resistance against smoking in public has increased considerably during 
the last decade, smoking still remains the most common form of substance abuse in our 
society. Tobacco was fIrst introduced in Europe in the sixteenth century by explorers 
returning from North and South America. There are various forms in which tobacco can be 
consumed. Smoking it in pipes was most preferred until the second part of the last century. 
With the manufacturing of cigarettes, at the end of the nineteenth century, tobacco 
consumption gradually shifted from chewing and smoking pipes to smoking cigarettes. 
Currently, in most Western countries about 35 % of the adult population consists of 
smokers!. 
After the second world war it became more and more evident that smoking is 
harmful to one's health. The main health risks caused by smoking are cancer and 
cardiovascular disease. Interestingly, it has recently become clear that beside the adverse 
effects, smoking also has some protective effects against certain disorders'·'·-·'. 
5.2 Pharmacodynamics of smoking and nicotine 
Although cigarette smoke contains more than six thousand components, nicotine 
seems to be the only pharmacologically active substance, present in large enough quantities, 
to cause systemic effects. The alkaloid nicotine is a tertiary amine composed of a pyridine 
and pyrrolidine ring. Nicotine binds to various types of acetylcholine receptors. According 
to their location these receptors can be divided in central nicotinic receptors (located in the 
central nervous system) and peripheral nicotinic receptors (located in the peripheral nervous 
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system). Central nicotinic receptors are primarily located in the hypothalamus, 
hippocampus, thalamus, midbrain, brain stem and certain segments of the cerebral corteX'·'. 
Stimulation of presynaptic central nicotinic receptors leads to activation of several 
neurohumoral pathways. This results in the release of various neurotransmitters and 
honnones such as acetylcholine, noradrenaline, dopamine, serotonin, vasopressin, growth 
hormone and adrenocorticotrophic hormone (ACTH)'·9.1O. 
The peripheral nicotinic receptors occur primarily in the autonomic ganglia and the 
striated muscles. Stimulation of the receptors in the sympathetic ganglia and adrenal medulla 
causes liberation of catecholamines from the adrenal medulla and release of noradrenaline 
from the atria and blood vessels". This results in sympaticomimetic effects such as 
vasoconstriction, tachycardia and increased myocardial contraction. 
The nicotinic receptors in striated muscle play an important role in neuromuscular 
transmission. Short-ternl stimulation, leading to a brief depolarization of the motor end plate 
and the membrane of the muscle cell, results in contraction of the striated muscle. Blockage 
of these receptors by non-depolarizing agents (e.g. pancuronium) causes a temporary 
paralysis. Paralysis can also be achieved by prolonging depolarization of the neuromuscular 
endplate with depolarizing compounds (e.g. suxamethonium), causing loss of electrical 
excitability!'. 
Receptors with a higb affmity for nicotine have recently also been reported on 
human lymphocytes13.14.!5. The exact function of these receptors has not yet been elucidated, 
but is seems likely that they would have a immunoregulatory role. 
5.2.1 Effects of cigarette smoking on the central nervous system 
The transport of nicotine across the blood-brain barrier is both a process of passive 
diffusion as well as active uptake by the choroid plexus!'. Although the effects of smoking 
on the central nervous system (CNS) are complex and diverse most smokers experience a 
state of arousal during and following smoking of cigarettes. Paradoxically, this is 
accompanied by a feeling of relaxation, especially in stressful situations. Furthermore, most 
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smokers report an improvement of their mood and ability to concentrate after smokingJ7 , 
One could argue that the enhanced performance and mood are the result of the reduction of 
withdrawal symptoms, However, improvement in the performance of nonsmokers following 
the administration of nicotine suggests a true enhancement", 
As is the case with most substances of abuse, nicotine stimulates the mesolimbic 
dopaminergic system", This might at least partly explain development of addiction, because 
this system plays an important role in reward mechanismi°, 
5.2.2 Endocrine system 
Several observations have been reported on smoking and stress, Especially female 
smokers, but also male smokers, albeit to a lesser extent, tend to increase their tobacco 
consumption in stressful situations"''',,,,,,, The number of cigarettes smoked and the 
intensity with which they are smoked increases, resulting in higher plasma nicotine levels 
than in a relaxing enviromnent", 
The one component in tobacco smoke that influences stress the most is nicotine", 
Nicotine enhances the release of corticotropin releasing factor (CRF) and ACTH from the 
hypothalamus and the pituitary respectively",27,,,, Both of these hormones stimulate the 
release of glucocorticoids from the adrenals, Thus, nicotine induces increased plasma levels 
of glucorticoids in animals26,29,3o, as well as in huma~I,32,3l. The increase in serum cortisol 
and corticosterone seems to be dose·dependent"''', 
5.2.3 Cardiovascular system 
Smoking a cigarette has multiple effects on the cardiovascular system of healthy 
smokers, The amount of nicotine absorbed from one cigarette leads to an increase in blood 
pressure of 5 to 10 mm Hg, in heart rate of 10 to 20 beats per minute and enhances cardiac 
output and coronary blood flow", In chronic smokers the cardiovascular effects of nicotine 
are less pronounced as a result of development of tolerance", 
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5.2.4 Gastrointestinal tract 
In the healthy individual nicotine has a stimulatory effect on the gastrointestinal 
tract, causing enhancement of gastric acid secretion and increase of tone and motili!)". 
Nicotine also plays a role in gastrointestinal pathology. Smoking prolongs the oesopbageal 
acid clearance time and increases the number of reflux events, thus it enhances oesophageal 
acid exposure". Furthermore, nicotine has been implicated in the initiation and maintenance 
of damage to the gastric mucosa". 
5.3 Ph31'macokinetics of smoking 
While smoking a cigarette the nicotine is carried on inhaled tar droplets. The rate of 
absorption of nicotine correlates positively with the pH of the smoke. Nicotine out of 
cigarettes causing smoke with a alkaline pH is readily absorbed, starting even in the oral 
cavity. Once the smoke has arrived in the small airways and alveoli the absorption becomes 
independent of the pH of the smoke. Smoking one cigarette yields on average 1 mg of 
nicotine38 • 
Nicotine obtained from smoking enters the brain more rapidly than intravenous 
administered nicotine, but the redistribution to other tissues also occurs at a high rate, 
resulting in a rapid decrease of the nicotine concentration in the brain. The ability to change 
the nicotine level so rapidly allows 'fine tuning' of the nicotine effects desired while 
smoking". This is also illustrated by the fact that when smokers are switched to cigarettes 
with lower nicotine content they smoke more cigarettes in order to achieve the amount of 
nicotine needed". Although nicotine is administered intermittently during the part of the day 
that the smoker is awake, it is being accumulated during this period because of the half-life 
of two hours. This enables the smoker to maintain a certain nicotine level as he sleeps ". 
Thus, nicotine exposure of a moderate smoker is of a chronic nature rather than of an 
intennittent one. 
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The metabolism of nicotine has been studied more extensively in trials with 
transdennal nicotine systems and will be discussed in the section concerning the 
pharmacokinetics of those systems (section 5.4.2). 
5.4 Tran.dermal nicotine 
The notion that nicotine is the component in tobacco responsible for the addiction to 
cigarette smoking has lead to the employment of nicotine replacement therapy to aid 
smoking cessation". The primary reason given for relapse after an attempt to stop smoking 
are the withdrawal symptoms". 
Nicotine reservoir 
Adhesive layer 
Internal membrane 
Blood capillary 
layer 
Skin surface 
Figure 5.1 Schematic representation of transdermal nicotine dilivery. 
The idea is to replace the nicotine that would otherwise have been obtained from the 
smoking of cigarettes, in order to reduce the withdrawal symptoms. Nicotine can be 
administered via various methods, such as chewing gum, nasal sprays and nicotine patches. 
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The amount of nicotine needed to prevent withdrawal symptoms is approximately 50 % of 
that obtained by smoking. 
5.4.1 Pharmacodynamics of transdennal nicotine 
Although little research has been published concerning the pharmacodynamics of 
transdermal nicotine administration, it seems unlikely that it would differ much from the 
effects of nicotine obtained from cigarettes, discussed in section 5.2. 
5.4.2 Pharmacokinetics of transdennal nicotine 
Pharmacological research concerning transdermal nicotine has mainly focused on the 
pharmacokinetic properties. Transdermal delivery has been employed to administer various 
drugs, such as glycerylnitrate, hyoscine, clonidine and oestrogens. Transdermal nicotine 
systems consist of a drug containing reservoir incorporated in a stick-on plaster. The 
amount of nicotine absorbed from these systems ranges from 35 to 90 %, depending on the 
system used"'''. Only a small proportion of the nicotine applied is lost resulting in a 
bioavailability of more than 80 %". After application, maximum plasma nicotine 
concentrations are reached within 3 to 12 hours. A dose-related increase in plasma nicotine 
levels has been reported following single application of different doses"·"·45. There is a 
gradual release of nicotine after application and plasma nicotine concentrations are still 
elevated at the end of the application period, followed by a gradual decrease after removal 
of the patch. Repeated transdermal administration of nicotine at 24 hour intervals yields a 
steady state within 2 to 4 days"''', but does not result in accumulation of nicotine, instead 
accumulation of cotinine occurs. 
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Studies of skin strips taken from individuals following application of transdermal 
nicotine patches did not detect cotinine in the epidennis. indicating lack of metabolism of 
nicotine in the skin". Metabolism of nicotine occurs primarily in the liver and to a lesser 
extent in the lung". The half-life of nicotine administered via smoking is approximately 2 
hours. albeit with a considerable interindividual variation. This is shorter than the 3 to 6 
hours reported for transdermally administered nicotine"''''''''''. An explanation for this 
difference could be the formation of a nicotine skin depot. leading to a sustained absorption 
of nicotine after the patch has been removed". The major metabolites of nicotine are 
eotinine and nicotine-N-oxide. 
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Figure 5.3 Metabolism of nicotine. 
In vitro studies have reported phannacological actions of cotinine'°, but in vivo it does not 
seem to have any cardiovascular effects in humans, nor does it influence the desire to 
smoke". This indicates that the previous mentioned accumulation of cotinine during 
repeated nicotine application probably does not have any clinical effect. Little research has 
been published concerning the pharmacological effects of the other metabolites of nicotine. 
Less that 10 % of the nicotine administered is excreted unchanged in the urine. Renal 
excretion however, is negatively correlated with the pH of the urine". In contrast to plasma, 
the primary metabolite excreted in urine is not cotinine but trans-3' -hydroxycotinine". 
5.5 Immunological aspects of smoking and nicotine 
Although the main interest of research on smoking and nicotine has been on the 
pharmacological effects on the central nervous system and the cardiovascular system, during 
the last two decades considerable attention has been given to the effects on the immune 
system. 
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In this section the effects of voluntary exposure to tobacco smoke on the immune 
system of animals and humans will be reviewed. Although, involuntary or environmental 
tobacco smoke exposure may also have significant effects On the immunological response, 
little information exists about this form of exposure to smoke. 
5.5.1 Studies in animals 
The effects of tobacco smoke on the immune system depends on various factors such 
as the species tested, the age of the animals tested, duration of exposure and the level of 
exposure. The most common test systems employ mice, rats and guinea pigs. The 
immunological effects of short-term or acute exposure are in general limited and return to 
normal soon after cessation of exposure. Subchronic or chronic exposure generally has a 
suppressive effect on the immune system. 
Shon-fenll exposure of animals fa tobacco smoke 
Tobacco smoke has been reported to cause changes in cellular as well as in humoral 
mediated immunity, however. not all authors agree on the effect on the humoral part. The 
differences reported may partly be due to differences in the set-up of the studies such as 
differences in the species used, differences in exposure level and differences in the types of 
cigarettes used. Thus short-term exposure of animals to tobacco smoke has been found to 
significantly inhibit, slightly stimulate or to have no effect on the primary and secondary 
antibody response". 
On the effect of tobacco smoke on the cellular immunity exists mOre agreement. 
Thomas and associates reported a decreased responsiveness to phytohemagglutinin (PHA) of 
peripheral blood and splenic lymphocytes isolated from mice exposed to cigarette smoke for 
5 weeksS5 . In contrast, the local pulmonary immune system was stimulated, resulting in an 
enhanced responsiveness to PHA of cervical and mediastinal derived lymphocytes. This 
suggests a differentiated initial response of local and peripheral immune system on antigens. 
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A very important issue when studying the effects of tobacco smoke is its influence 
on the host-resistance to tumor formation. In a study by Thomas et al. exposure to cigarette 
smoke for 3 days did not stimulate tumor growth in mice following intratracheal injection of 
two different types of tumor cells". 
Chronic exposure of animals to tobacco smoke 
Most studies report decreased humoral immune response after chronic exposure to 
cigarette smoke. Findings reported are a decreased primary and secondary antibody 
production by cells in the lung, lymph nodes and spleen"'" and diminished hemagglutinin 
and haemolytic antibody titers". In contrast to the differentiated response upon short-time 
exposure to cigarette smoke, the effects of chronic exposure are similar for the local and the 
peripheral immune system. Lymphocytes from peripheral blood and spleen as well as from 
regional lymph nodes, derived from mice chronically exposed to tobacco smoke, show a 
diminished response to PHA stimulation in comparison to cells from control animals"'''. 
Contrary to the lack of effect on host-resistance against tumor genesis reported for short-
time exposure, chronically exposed animals exhibit a severely decreased resistance against 
the development of tumors following inoculation with tumor cells"'·61.". 
Chronic exposure to cigarette smoke naturally also causes multiple local 
immunological changes in the lungs. such as an increase in number and in metabolic rate of 
pulmonary macrophages"· .. ·.,. It is however, highly improbable that these local changes in 
the lung would play an important role in the effects smoking has on inflanunatory bowel 
disease and for this reason they will not be discussed. 
5.5.2 Studies in humans 
Effects of tobacco smoke on the cellular immune system 
As early as 1940 Scheer reported an increased leukocyte count in peripheral blood of 
smokers". This rmding has been confirmed by many authors"·6S·". The extent of the 
leukocytosis caused by smoking seems to depend on race, gender, age and the amount of 
88 
CIUlpter 5 
cigarettes smoked67.". These variables, in combination with the small sample size, may 
explain the conflicting reports published about the effects of cigarette smoking on human 
T -lymphocytes. Some authors report a significant decrease in the CD4 + /CD8 + 
ratio71•12,13.14, while others find no change or even an increased helper/suppressor 
ratio67.".".77. Among studies reporting the effects of smoking on B-Iymphocytes there is 
considerably more agreement. The overall majority of these studies report an increased 
number of B~cel1 in smokers61.7S,16,71,18,19, 
The effects of smoking on lymphocyte function have, if possible, been the object of 
even more debate than the influence of smoking on T-cell subsets. The influence of 
phytohemagglutinin stimulated proliferation seems to depend strongly on the age of the 
smokers tested, with an enhanced proliferation in young individuals and an inhibition in 
older smokers, compared to nonsmokers of the same age group"'''. Other authors did not 
observe any influence of cigarette smoking on PHA, concanavalin A or alloantigens-induced 
proliferation16,82.83,84 , 
Tobacco consumers have a far greater change of developing tumors than 
nonsmokers. This increased incidence does not only apply for malignancies located in the 
lung and oral cavity, but also for those in organs which do not come in direct contact with 
tobacco or tobacco smoke"''''''. This suggests suppression of not only the local but also of 
the more general defense mechanisms against carcinogenesis in these individuals, Natural 
killer (NK) cells play a major role in tumor resistance and for this reason considerable 
research has been carried out concerning the effect of tobacco smoke on NK cell activity in 
smokers. Indeed, several studies have reported a decreased NK cell activity in leukocytes of 
smokers68,76.88.89. 
Effects of tobacco smoke Oil the humoral il1lll11me system 
Most authors agree that the immunoglobulin levels are decreased in smokers, except 
IgE levels"· .. ·,,,·9l·,,·.,. The elevated IgE levels found in smokers are often accompanied by 
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eosinophilia94,95,96.97, Interestingly however, the correlation between eosinophilia, IgE levels 
and skin reactivity seen in nonsmokers, bas not been found for smokers", 
5.5.3 In vitro and in vivo studies with nicotine 
Because tobacco smoke consists of so many components it is difficult to establish 
which of these components is responsible for the inununoregulatory effects. There are 
however. many pieces of evidence suggesting a major role for nicotine. 
Allimal sludies 
Tobacco smoke can be divided in a particulate and a gaseous phase with the help of a 
Cambridge filter. These two phases are of a different composition, with nicotine being a 
major constituent of the particulate phase". The particulate phase of tobacco smoke is 
essential for the inununosuppressive effect of cigarette smokeloo. Furthermore, 
administration of nicotine to animals have been reported to cause various effects on their 
cellular and humoral inunune systemlOl ,102.103,IN,105,I06. 
Human studies 
Nair el al. studied the ill vilro effect of nicotine on NK cell activity in human 
lymphocytes and found a significant suppressionlO'. The ill vitro inununoglobulin production 
has also been shown to be modulated by nicotine, albeit in a different pattern than by 
smokinglO8 . Furthermore, nicotine has a significant influence on the in vitro production of 
mediators of inflammation. Saareks and associates reported that nicotine causes a dose-
dependent increase of prostaglandin E, production and a decrease of leukotriene B, synthesis 
by polymorphonuclear leukocytes. The same authors also observed a reduced thromboxane 
B, production in platelet rich plasma following incubation with nicotine109. In a study on the 
effect of nicotine on ill vitro cytoldne production by human mononuclear cells we found a 
significant inhibition of the PHA-stimulated production of tumor necrosis factor " and 
interleukin 2, reaching its maximum effect at nicotine concentrations equivalent to nicotine 
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levels measured in the plasma of smokersllo. Recently, prolonged neutrophil survival has 
been reported, after incubation with nicotine. This effect was subscribed to suppression of 
apoptosis by nicotinelll . 
In agreement with these ill vilro findings are the reports by Pullan el 01.112 and 
Lasher et al. 113 on the beneficial effects of nicotine administered transdennally or orally in 
ulcerative colitis. 
5.6 Conclusion 
A Iherapeulic role for nicoline? 
The epidemiological finding that smoking is associated with a decreased incidence of 
certain disorders suggests that nicotine might have beneficial effects in some diseases. The 
availability of nicotine in easy administrable fonns has lead to the implementation of clinical 
trials to study the efficacy of nicotine in the treatment of these disorders'I2·I13·II4. Although, 
the data of these studies are promising, showing significant clinical improvement and a 
reasonable tolerability of nonsmokers for nicotine treatment, it has not yet become a 
established therapy for these patients. Most worrying are of course the potential addictive 
power, and the cardiovascular and carcinogenic side effects. 
In a large randomized, double-blind, controlled trial in patients with active ulcerative 
colitis, Pullan el al. reported no evident withdrawal symptoms after six week treatment with 
nicotinel12 • The authors ascribe the lack of withdrawal symptoms to the steady release of 
nicotine by transderrnal nicotine patches, which does not cause the sharp increases in plasma 
nicotine concentrations measured following smoking. In this study, patients did not 
experience serious adverse effects necessitating medical treatment. Other authors however, 
have reported serious cardiovascular complications during transdermal nicotine 
treatment llS,1l6. Further investigation is needed to unravel the exact mode of action of 
nicotine in these disorders. Knowledge of the exact mechanisms involved might enable the 
development of agonists more acceptable than nicotine itself. 
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Chapter 6 
Nicotine inhibits cytokine production by mouse colonic mucosa', 
Abstract - We examined the ill vivo effect of nicotine on the synthesis of mediators 
of inflammation by mouse colonic mucosa. The synthesis of lipid mediators such as 
the prostanoids prostaglandin E" 6-keto-prostaglandin F,. and thromboxane B2, the 
5-lipoxygenase products leukotriene B, and leukotriene C, and platelet activating 
factor was not affected, whereas the synthesis of the pro-inflammatory cytokines 
interleukin 16 and tumor necrosis factor" was significantly inhibited. 
6.1 Introduction 
Recent studies have shown that transdermal application of nicotine in patients with 
active ulcerative colitis has a beneficial effect on the symptoms of this disease'. 
Exposure of animals to tobacco smoke has been reported to cause a decreased humoral 
reponse. Findings reported are a decreased primary and secondary antibody production by 
cells in the lung, lymph nodes and spleen'" and diminished hemagglutinin and haemolytic 
antibody titers'. Lymphocytes from peripheral blood and spleen as well from regional 
lymph nodes show a diminished response to PHA stimulation in comparison to cells from 
control animals2,s. 
The effects of nicotine on lipid mediators such as prostaglandins are still 
controversial. In rabbits prostaglandin production was inhibited by nicotine in a inverse 
dose dependent manner, whereas in ferrets no significant effects were observed'. 
'Based all: Van Dijk A.P.M., Madretsma G.S., Keuskamp Z.J., Zijlstra F.J. 
Nicotine inhibits cytokine production by mouse colonic mucosa. EliI'. J. Pharo 
1995;278:Rll-RI2. 
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This study is based on very strong epidemiological evidence that identifies ulcerative 
colitis as predominantly a disease of non-smokers'. The mechanism underlying this 
beneficial effect of nicotine is unknown. In order to fmd an explanation for this response to 
nicotine we investigated the ill vivo effect of nicotine on lipid mediators and cytokines 
produced by colonic mucosa in mice. 
6.2 Methods 
This study was approved by the Animal Experimental Committee of the Erasmus 
university of Rotterdam. 
Colonic mucosa was obtained from 15 BALB/c female mice (19-21 g). Nine mice 
were used as controls, six mice were treated with nicotine. Initially t mice received nicotine 
in drinking water ad libitlllll: 2 days 25 I'g/ml, 2 days 50 I'g/mI, 2 days 100 I'g/ml and 2 
days 200 Jlg/mI. Thereafter nicotine was dissolved in saline and given during 14 days 
subcutaneously by an Alzet osmotic mini-pump with an infusion rate of 200 I'g/day. 
Controls, nine mice, received tap water and an osmotic pump ftlled with saline. The 
concentration of nicotine and cotinine in plasma reflected the dose of nicotine given. 
After the mice were killed by cervical dislocation the colon from the hepatic flexure 
to the rectum was removed immediately. The colon was opened in transverse direction and 
faeces removed. The weight of the colon was determined and 2 mI Krebs-Henseleit buffer 
added, after which the tissue (approximately 200 mg) was fragmented using an Ultra-Turrax 
(Polytron, Switzerland) and centrifuged for 15 min. at 10.000 x g. The amount of protein 
per mg wet homogenized tissue was determined by a micro-scale method. 
Eicosanoids were determined by radioimmunoassay, using antibodies from 
Advanced Magnetics (MA, USA), tritiated compounds from Arnersham (UK) and standards 
from Sigma Co. (USA). Platelet activating factor was determined by radioimmunoassay 
(PAF-SPA system, Arnersham, UK) and cytokines by enzyme-linked immunosorbent assay: 
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tumor necrosis factor a from Genzyme Corp. (USA) and interleukin-llI from Cistron 
Biotechnology (Eurogenetics, Belgium). 
6.3 Results 
After 3 weeks of treatment plasma nicotine and cotinine concentrations were 
3.6 ± 0.6 (mean ± S.E.M.) and 0.3 ± 0.05 nglml in controls and 42 ± 3.0 and 105 ± 11 
nglml in nicotine treated mice respectively. These data are equivalent to plasma cotinine 
levels in patients treated with nicotine patches with a release of 15 mg nicotine per day, 
reflecting 15 cigarettes per dayl. 
The synthesis of lipid mediators was unaffected, whereas the production of IL-IB 
and TNPa significantly inhibited (table 6.1). 
Mediator Controls Nicotine 
Protein (J<glmg) 11.8 ± 0.69 12.5 ± 0.52 
6~keto·prostaglandin F1a (pglmg) 3620 ± 428 3500 ± 341 
Prostaglandin E, (pglmg) 1020 ± 157 1170 ± 73 
Thromboxane B2 (pglmg) 416 ± 53 415 ± 32 
Leukotriene B4 (pglmg) 3.4 ± 0.42 2.9 ± 0.28 
Leukotriene C4 (pglmg) 1.5 ± 0.27 1.8 ± 0.39 
Platelet activating factor (pglmg) 54 ± 20 48 ± 14 
Interleukin-l p (pglmg) 1.3 ± 0.60 < 0.1 " 
Twnor necrosis factor a (pglmg) 120 ± 58 13± 13" 
Table 6.1 Formation of lipid mediators and cytokines by mouse colonic mucosa after nicotine 
treatment .. P<O.05 compared with controls. 
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6.4 Discussion 
This is, as far as we know, the fIrst study in which the direct effect of nicotine on 
the synthesis of pro-inflammatory cytokines was investigated and shown to be of a strong 
inhibitory Dature. Recently the effect of exposure to cigarette smoke was investigated in 
alveolar macrophages in rats8 . As expected tumor necrosis factor a was increased in 
alveolar macrophages, but surprisingly decreased in peritoneal macrophages 8 hours after 
the smoking session. In that study peritoneal macrophages were taken as internal control 
cells and the authors failed to conclude that this unexpected effect could be due to 
circulating nicotine. 
Both TNPa and IL-16 are thought to be important cytokines involved in the initial 
events preceding the further development of inflammation in the gastrointestinal tract. 
Although TNPa and IL-16 are mainly produced by macrophages', other cells also secrete 
TNFa. It has been shown that TNPa producing cells are increased in the mucosa of 
inflamed intestine wOur results offer a possible explanation for the benefIcial effects of 
nicotine in ulcerative colitis. 
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Chapter 7. 
Nicotine inhibits the in vitro production of inter leu kin 2 and tumor 
necrosis factor a by human mononuclear cells' 
Abstract - Smoking protects against ulcerative colitis (UC), and treatment with 
nicotine patches has a beneficial symptomatic effect in patients with UC. To fmd an 
explanation for this response to nicotine in UC, we assessed the effects of nicotine 
on cytokine production by mononuclear cells (MNC). MNC were isolated from 
peripheral blood from healthy volunteers. Non-adherent MNC were preincubated 
with varying concentrations of nicotine or prednisolone for 24 hours followed by 
addition of phytohemagglutinin (10 I'g/ml). The concentrations of interleukin 2 
(IL-2) and tumor necrosis factor a (TNFa) in the supernatants were determined by 
ELISA. 
Nicotine as well as prednisolone caused a significant inhibition of IL-2 and TNFa 
production. The maximum inhibition caused by nicotine was about 50 % of that 
caused by prednisolone and was reached at concentrations equivalent to nicotine 
levels measured in plasma of smokers. 
These results indicate that nicotine exerts its immunoregulatory role through 
modulation of the cytokine production by non-adherent mononuclear cells. 
7.1 Introduction 
During the last decade it has become clear that cigarette smoking not only increases 
the risk of developing cancer' or cardiovascular disease', but surprisingly, also has 
'. Based 011: Madretsma G.S., Donze G.J., van Dijk A.P.M., Tak C.J.A.M., 
Wilson J.H.P., Zijlstra F.J. Immllllophannac%gy. 1996;35:47-51. 
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beneficial effects on some chronic diseases such as Alzheimer disease' and ulcerative 
colitis"'. Although the mechanisms underlying these beneficial effects are unknown, there is 
evidence that smoking influences the cellular' as well as the humoral immune system""'. 
Cigarette smoke contains a range of compounds with pharmacological activity. Of 
these compounds nicotine is the most important and it therefore seems logical to assume it 
to be responsible for most of the immunoregulatory effects of cigarette smoke. Treattuent of 
patients with active ulcerative colitis (UC), a form of inflammatory bowel disease, with 
nicotine patches proved to have a beneficial effectlO • The application of transdermal nicotine 
significantly improved symptoms in these patients. Nicotine may therefore have anti-
inflammatory properties which could be important in the treattuent of UC. 
Recent studies have indicated an important role for T-cells in inflammatory bowel 
disease (lED), especially in the initial phase of the inflammation. Cytokines produced by 
these cells playa key role in the pathogenesis of IBD. Elevated levels of TNPa and IL-2 
have been reported in serum and stool of patients suffering from IBD, for most other 
cytokines there have been conflicting reports or they have not been adequately 
investigated ". 
In order to find an explanation for the beneficial effect of nicotine in ulcerative 
colitis we examined the effect of nicotine on the production of two important mediators of 
inflammation in inflammatory bowel disease, interleukin 2 (IL-2) and tumor necrosis 
factor a (TNPa). 
7.2 Materials and Methods 
Approval for this study was obtained from the Medical Ethical Committee of the 
University Hospital of Rotterdam. 
Isolation of mononuclear cells 
Mononuclear cells (MNC) were isolated from 60 ml heparinized venOUS blood 
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immediately after blood sampling. The method used was a modification of the technique 
described by Boyum". Briefly, the blood was diluted 1:1 with Phosphate Buffered Saline 
(PBS; Oxoid, U.K.) before fractioning it by a one-step Ficoll-Paque gradient (pharmacia, 
Sweden) centrifugation at 1100 g for 15 minutes at 20 'C. The interphase was washed in 
PBS and resuspended in Dulbecco's Modified Eagles Medium (DMEM) containing HEPES 
and foetal calf serum (Gibco, U.K.), supplemented with penicillin and streptomycin ( Flow 
Lab, U.K.). 
Following isolation the MNC were incubated in culture medium for 90 minutes in a 
water saturated atmosphere of 37 'c containing 5 % Co,. Non-adherent MNC were 
harvested by repeated rinsing of the culture flasks (Costar, U.S.A.) with DMEM. The 
viability of the cells, assessed by Trypan blue exclusion, was over 95 %. 
Characterization of non-adherent mononue/ear cell fraction 
The leucocyte subpopulations present in the non-adherent MNC fraction were 
analyzed by FACS using the monoclonal antibodies Leu 4, Leu11 and Leul9 (Becton 
Dickinson, Mountain View, CAl that recognize CD3, CD16 and CD19 respectively. CD14 
and CD20 positive cells were characterized by My 4 and B4 (Coulter Cytometry, Florida) 
Stimulation experiments 
Non-adherent MNC were cultured (2 x 10' cellsl well) in 24 wells culture plates 
(Costar, Cambridge MA, USA) in the absence or presence of varying concentrations of 
nicotine-hydrogen-tartrate (BDH Ltd Poole, U.K.) or prednisolone-di-sodium-phosphate 
(Genfamoa, The Netherlands) for 24 hours, followed by addition of phytohemagglutinin 
(pHA: 10 I'g/ml; Sigma Chemie, Belgium). After incubation for another 24 hours 
supernatants were harvested and stored at -80 'c until IL-2 and TNFa concentrations were 
assessed by ELISA (IL-2: Medgenix, Belgium, sensitivity: 70 pg/ml and TNFa: C.L.B., 
The Netherlands, sensitivity: 3 pg/ml). The concentration of IL-2 and TNFa produced in 
the presence of PHA and absence of nicotine and prednisolone was used as control and set 
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at 100 %. All incubations were perfonned in duplicate. 
Statistics 
The IL-2 and TNPu production are expressed as mean ± S.E.M.(n= 5). Statistical 
comparisons between control and drug-treated cell cultures were made by paired t-test. 
A P <0.05 was considered significant. 
7.3 Results 
The non-adherent MNC fraction consisted primarily of T-lymphocytes (table 7.1). 
The PHA-stimulated TNPu production ranged from 3580 to 5430 pg/ml, with a mean ± 
S.E.M of 4585 ± 360 pg/ml and a median of 4810 pg/ml. Por IL-2 we measured a range of 
1000 - 2660 pg/ml, with a mean of 1615 ± 295 pg/ml and a median of 1590 pg/ml. 
Cluster differentiation Percentage 
CD3 72.1 ±2.3 
CDI6/CD56 15.1 ±0.8 
CD20 7.3 ± 1.9 
CDI4 0.6 ±O.I 
Not classified 4.9 ±1.2 
Table 7.1. Percentage of different cell types comprising the non-
adherent mononuclear cells. Cells were characterized by FACS using 
the monoclonal antibodies Leu 14, Leu 11. Leu 19. B4 and My 4. 
The production of IL-2 and TNPu by these cells was inhibited in a dose dependent 
manner when nicotine was added 24 hours prior to PHA (figure 7.1). This inhibition was 
only partial. Por IL-2 the maximum effect of nicotine was observed at 10' M (figure 7.1a) 
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Figure 7.1 Effects of nicotine (solid dot) and prednisolone (open triangle) 
on the synthesis of interleuk!n 2 (a) and tumor necrosis factor a (b) in 
cultures of human peripheral blood lymphocytes stimulated with 
phytohemagglutinin (PHA: 10 pg/ml). Cytokine production (percentage of 
control) is presented as mean ± S.E.M. (vertical bars) and represent 5 
experiments performed on non adherent mononuclear cells obtained from 5 
separate healthy volunteers. The paired I-test was used to compare control 
and drug-treated cell cultures. Prednisolone and nicotine caused a 
significant inhibition of cytokine production, :Ii< P< 0.05; **p < 0.01 
compared with control cultures incubated with DMEM and PHA. 
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and for TNFa at 10-8 M (figure 7.lb). A further increase of the nicotine concentration did 
not enhance the effect. There was a considerable interindividual variation in response to 
nicotine but enhanced production of the cytokines after addition of nicotine was never 
observed. 
Addition of nicotine and PHA simultaneously or addition of nicotine after PHA, in 
contrast, had no effect on IL-2 and TNFa production. Nicotine did not influence the 
viability of the cells, even in the highest concentration used (J()" M). 
Treatment of the non-adherent MNC with the corticosteroid prednisolone, also 
caused a dose dependent inhibition of IL-2 and TNFa production. As with nicotine, the 
addition of prednisolone had to proceed that of PHA in order to cause a significant 
inhibition of IL-2 and TNFa production at the lower doses. In contrast to nicotine, the 
effect of prednisolone did not reach a plateau at the concentrations tested. 
7.4 Discussion 
The results of this study show that nicotine inhibits the ill vitro production of IL-2 
and TNFa by human non-adherent MNC. This is in agreement with our recent observation 
of an inhibition of cytokine production by mouse colonic mucosa after treatment with 
nicotine13 . 
The inhibition of IL-2 and TNFa production by human MNC appears to be 
dependent on the concentration of nicotine, the duration of incubation and the individual 
donor. The potency of nicotine, however, was about 50 % of that of prednisolone, a potent 
glucocorticosteroid. It is at present not clear whether nicotine administered transdermally is 
less effective clinically than prednisolone, as the clinical observation by Pullan et at was on 
an additional anti-inflammatory effect of nicotine added to maintenance therapy with 
corticosteroids or 5-aminosalicylic acid, in the treatment of ulcerative colitis. In this study, 
nicotine reached its maximum effect at concentrations equivalent to those measured in 
plasma of smokers". 
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We chose to use a cell population consisting predominantly of T-cells in this study 
for two reasons. Recent study has proven cyclosporin to be effective in the treatment of 
ulcerative colitis refractory to steroid therapy". Cyclosporin exerts its immunosuppressive 
effect by suppressing the induction and amplification of T-cell responses by inhibiting 
cytokine gene activation, particularly IL-216. Another finding indicating an important role 
for the T-cell in the pathogenesis of ulcerative colitis is the observation that appendectomy 
has a protective effect against ulcerative colitis. The appendix is a helper T-cell orgarr'. 
Inhibition of TNPu production by nicotine offers not only a possible explanation for 
the beneficial effect of this drug in UC but could also shed some light on the role smoking 
plays in the development of cancer. Smoking does not only elevate the risk of lung cancer 
but also of cancer in organs which do not come in contact with smoke itself'·I9·". A 
possible contributory factor to this carcinogenic effect of smoke 'at a distance' is that 
nicotine causes a more or less general suppression of the immune system, rendering the 
individual more susceptible for the development of neoplasms. 
We conclude that nicotine has immunoregulatory effects through modulation of the 
cytokine production by non-adherent mononuclear cells. 
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Nicotine induced inhibition of interleukin 2 and tumor necrosis factor a 
production by human mononuclear cells is mediated via a noncholinergic 
receptor' 
Abstract - Nicotine has been shown to affect the cellular as well as the humoral 
immune system of animals and humans, and ill vitro and in vivo nicotine influences 
cytokine production. 
We recently found an inhibition of human mononuclear cell produced IL-2 and 
TNPu by nicotine. 
Human leukocytes possess receptors for nicotine. but these receptors have not yet 
been characterised. In order to establish an innnunological role for these receptors 
we set out to demonstrate their involvement in the inhibition of cytokine production 
by nicotine. 
Non-adherent MNC were preincubated in the presence or absence of two cholinergic 
nicotine receptor antagonists, hexamethonium and pancuronium, followed by the 
addition of nicotine and phytohemagglutinin. The concentrations of IL-2 and TNPu 
in the supernatants were determined by ELISA. In addition. ligand binding studies 
and displacement experiments were conducted to confIrm the presence of receptors 
for nicotine on the MNC and to further characterize these receptors. 
Interleukin 2 and TNPu production was significantly inhibited by nicotine. 
However. this inhibition could not be blocked by hexamethonium or by 
'Based all: G.S. Madretsma. A.P.M. van Dijk. C.J.A.M. Tak. J.H.P. Wilson. P.J. 
Zijlstra. Submitted. 
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pancuronium. The MNC had 2630 ± 350 nicotine receptors / cell (mean ± S.B.M.) 
with a Kd of 6.2 ± 1.4 nmolll. The nicotine receptor present on the MNC had no 
affinity for any of the cholinergic agonists and antagonists tested. 
These results indicate that nicotine inhibits the production of IL-2 and TNFa by 
peripheral blood MNC via a non-cholinergic nicotine receptor. 
8.1 Introduction 
Cigarette smoking has multiple effects on the inunune system of animals as well as 
humans. Administration of nicotine to animals have been reported to affect their cellular and 
humoral immune system'·'·3.4·,·,. Nair et 01. studied the ill vitro effect of nicotine on natural 
killer cell activity in human lymphocytes and found a significant suppression'. Furthermore, 
nicotine modulates inununoglobulin production' and has a significant influence on the ill 
vitro production of mediators of inflammation. Saareks and associates reported that nicotine 
causes a dose-dependent increase of prostaglandin E, production and a decrease of 
leukotriene B, synthesis by polymorPhonuclear leukocytes. The same authors also observed 
a reduced thromboxane B, production in platelet rich plasma following incubation with 
nicotine9• Recently, prolonged neutrophil survival has been reported, after incubation with 
nicotine. This effect was subscribed to suppression of apoptosis by nicotinelO • 
In a study on the effect of nicotine on ill vitro cytokine production by human 
mononuclear cells we found a significant inhibition of the PHA-stimulated production of 
tumor necrosis factor a and interleukin 2, reaching its maximum effect at nicotine 
concentrations equivalent to nicotine levels measured in the plasma of smokersll . 
Leukocytes contain receptors for a number of compounds such as acetylcholine", 
corticosteroids13, pz-agonists l4, opiates 15 and insulinl6• 
In this study ligand binding experiments were performed to demonstrate the presence 
of binding sites with a high affinity for nicotine on human non-adherent mononuclear cells. 
In order to test the hypothesis that nicotine inhibits cytokine production through a 
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cholinergic nicotine receptor we perfonned in vitro experiments with mononuclear cells and 
nicotine in the presence or absence of two cholinergic nicotine receptor antagonists, 
hexamethonium and pancuronium. 
8.2 Materials and Methods 
Approval for this study was obtained from the Medical Ethical Committee of the 
University Hospital of Rotterdam. 
Isolation of mononllclear cells 
Mononuclear cells were isolated from heparinized blood obtained from 5 healthy 
non-smokers. The isolation took place immediately after blood sampling and cell were 
characterized as described previouslylI 
Cytokine prodllction 
Non-adherent MNC were cultured (2 x Ht cells I well) in 24 wells culture plates 
(Costar, Cambridge MA, USA) in the presence or absence of the cholinergic nicotine 
receptor antagonists hexamethonium (10" mol/l) (Sigma Chemie, Belgium) or pancuronium 
(10" molll) (Organon Teknika B.V., The Netherlands). After 60 minutes varying 
concentrations of nicotine-hydrogen-tartrate (BDH Ltd Poole, U.K.) were added to the 
wells. Pollowing incubation for 24 hours, phytohemagglutinin (FHA: 10 I'g/ml; Sigma 
Chemie, Belgium) was added, and the incubation continued for another 24 hours. At the end 
of the incubations, the supernatants were harvested and stored at - 80 °C until IL-2 and 
TNP" concentrations were assessed by ELISA (IL-2: Medgenix, Belgium, sensitivity: 70 
pg/ml and TNP,,: C.L.B., The Netherlands, sensitivity: 3 pg/ml). The concentration of the 
cytokines produced in the presence of PHA and the absence of nicotine, hexamethonium and 
pancuronium was used as control and set at 100 %. All incubations were perfonned in 
duplicate. 
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Nicotille receptor billdillg studies 
Binding to nicotine receptors was measured using a binding assay with N-methyl)H-
nicotine (Amersham, U.K.). All incubation were performed in triplicate. A stock cell 
solution of 10 x 10' cells per ml in Hanks' Buffer without calcium and magnesium (Life 
Technologies B.V., The Netherlands) was kept at 4 'C for 30 minutes. Aliquots of 100 1'1 
of this solution were added to polypropylene tubes containing 50 pi Hank's buffer with or 
without an excess of nicotine, or 50 pi of the appropriate tritiated nicotine concentration. 
After an incubation of 15 minutes at 4 'c the assay was concluded by adding 4 ml ice cold 
Phosphate Buffered Saline (pBS; Oxoid, U.K.), followed by an incubation on ice for 30 
minutes. The content of each tube was brought on glass microfibre filters (Whatrnan 
International LTD, U.K.) under vacuum. The filters were flushed 3 times with 4 ml ice cold 
PBS. After drying, filters were placed in econo glass vials (Canberra-Packard Benelux 
N. V., The Netherlands) and kept overnight to enable solubilization after addition of 5 ml 
Emulsifier Scintillator Plus (Canberra-Packard Benelux N.V., The Netherlands). The 
amount of radioactivity in each vial was measured using a Liquid Scintillation Analyzer 
(packard Instrument B.V., The Netherlands). 
Specific binding was determined by subtracting the amount of nonspecifically bound 
radioligand from the total amount bound. Data were analyzed by constructing a Scatchard 
ploe'. 
Dispiacemelll of tritiated llicotille by various drugs 
In order to further characterize the binding sites on the non-adherent MNC we 
performed displacement experiments with various compounds. These compounds included 
known cholinergic agonists and antagonists (table 8.2). Furthermore, we tested compounds 
known to inhibit ill vitro cytokine production by human non-adherent MNC. 
Displacement experiments were performed as described above for 'tritiated nicotine 
receptor binding studies', with the difference that a single concentration of tritiated nicotine 
and multiple concentrations of the drugs tested were used. 
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Statistics 
IL-2 and TNFa production are expressed as mean ± S.E.M. (n = 5). Statistical 
comparison between control and drug-treated cell cultures were made by paired t-test. 
A P-value < 0.05 was considered significant. Plots of nicotine-treated cultures in the 
absence of antagonist were compared with plots in the presence of antagonists using 
Manova. 
Cluster differentiation Percentage 
CD3 70.4 ±2.5 
CD 16/CD56 16.1 ±0.7 
CD20 7.5 ±1.7 
CD14 0.9 ±0.2 
Not classified 5.1 ± 1.3 
Table 8.1 Non·adherent mononuclear cells subdivided in the different cell type 
by FACS. The antibodies used were Leu 14, Leu 11, Leu 19, B4 and My4. 
8.3 Results 
Effect 011 cytokine productioll 
The eel! fraction used consisted predominantly of T-Iymphocytes (table 8.1). 
Phytohemagglutinin stimulation resulted in an IL-2 production ranging from 840 to 2470 
pg/ml. with a mean ± S.E.M. of 1480 ± 255 pg/ml and a median of 1465 pg/ml. For 
TNFa the range was 3740 - 5570 pg/ml. mean ± S.E.M 4690 ± 340 and the median 4960 
pg/ml. Nicotine caused a dose-dependent inhibition of both cytokines. Pre-incubation of the 
non-adherent MNC with the cholinergic nicotine receptor antagonists hexamethonium and 
pancuronium did not block the effect caused by nicotine (figure 8.1). 
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Assessment of nicotine receptor number and Kd in non-adherent MNC. 
In figure 8.2, a representative Scatchard plot from one of the ligand binding 
experiments with tritiated nicotine is shown. The slope is equal to the negative reciprocal of 
the dissociation constant (-I/K.,) and the intercept on the abscissa equals the total 
concentration of receptors (B=). The nicotine receptor content for the non-adherent MNC 
was 2630 ± 350 sites I cell (mean ± S.E.M.) with a K;, of 6.2 ± 1.4 omolil. 
Displacement studies 
Tritiated nicotine was most effectively displaced by unlabeled I-nicotine. None of the 
other compounds tested inhibited the binding of tritiated nicotine. Table 8.2 depicts the 
drugs tested and the percentage inhibition of tritiated nicotine binding. 
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Drugs 
I-Nicotine 
Cotinine 
Carbachol 
Atropine 
Dimethylphenylpiperazinium (DMPP) 
Hexamethonium 
Pancuronium 
Prednisolone 
Dexamethasone 
Isoprenaline 
Salbutamol 
Inhibition (%) 
100 
< 10 
< 10 
< 10 
< 10 
<10 
<10 
< 10 
< 10 
< 10 
< 10 
Table 8.2 Effect of cholinergic agonists, antagonist and compounds known to inhibit 
cytokine production by non-adherent MNC on the binding of tritiated nicotine to the 
receptor. All drugs, except cotinine, caused less than 10 % inhibition at HX>O fold excess. 
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Figure 8.1 Effect of nicotine in the absence (solid dot) or presence of 
hexamethonium (open triangle) or pancuronium (open square) on the ill 
vitro production of IL-2 and TNFa by human peripheral lymphocytes. The 
lymphocytes were stimulated with phytohemagglutinin (PHA: lO pg/ml). 
Cytokine production (percentage of control) is presented as mean ± S.E.M. 
(vertical bars) and represent 5 consecutive experiments perfonned on cells 
obtained from 5 separate healthy volunteers. The paired I-lest was used to 
compare conlrol and nicoline trealed cell cwtures. Nicotine caused a 
significant inhibition of IL·2 and TNPa production, * P < 0.05 compared 
with control cultures incubated with medium and PHA. The effect nicotine 
is not blocked by the cholinergic nicotine receptor antagonists 
hexamethonium (a and c) and pancuronium (b and d). 
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Figure 8.2 Scatchard plot of specifically bound N-methyPH-Nicotine to 
non-adherent mononuclear cells. ~ and BmU in the case shown are 2.44 
nmolll and 2.33 fmolll06 cells respectively. 
8.4 Discussion 
Epidemiological studies have reported an inverse association between cigarette 
smoking and several inflammatory and immunological disordersI8.19.20,21.22,2},24. 
Subsequently, nicotine administration has been shown to have beneficial effects in ulcerative 
colitis"'''. Cigarette smoking and nicotine have been reported to affect various actions of 
the inunune system, including lymphocyte function and cytokine production'·I1·". 
The presence of receptors on human lenkocytes with a high affInity for nicotine was 
first suggested almost two decades ago". Data from our study confirm the presence of these 
receptors on human non-adherent MNC. However, little is known about the function of this 
type of receptor. In this study we set out to establish the plausibility of their inununological 
role by proving their involvement in the nicotine induced inhibition of cytokine production. 
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The fact that inhibition of cytokine production by nicotine could not be blocked by two 
types of cholinergic nicotine receptor antagonists suggests that these receptors are of a 
noncholinergic nature. Further evidence for this hypothesis is provided by the inability of 
multiple cholinergic agonists and antagonists to displace tritiated nicotine from the receptor. 
Another possible explanation of a receptor mediated inhibition of cytokine 
production by nicotine is that nicotine exerts its anti-inflammatory effects through another 
type of known receptor. This assumption implies that receptors present on non-adherent 
MNC which mediate the anti-inflammatory effects of another compound would also have a 
high affinity for nicotine. A number of receptors present on human leukocytes are known to 
mediate anti-inflammatory effects, such as inhibition of ill virro cytokine production. 
Examples are the receptor for glucocorticoids" and p,-adrenoceptor agonists". The 
glucocorticoids as well as the p,-adrenoceptor agonists tested in the displacement 
experiments failed to inhibit binding of tritiated nicotine to the receptor. This suggests that 
the receptor present on non-adherent MNC, to which tritiated nicotine binds, is neither the 
glucocorticoid receptor nor the p,-adrenoceptor. 
There are multiple methods to characterize receptors. In this study we used dose 
response curves in the presence or abcense of 2 types of known nicotine receptor 
antagonists. The fact that these antagonists could not block the effect of nicotine could also 
implie that the effect of nicotine is not receptor mediated. However, ligand binding studies 
established the presence of binding sites on MNC with a high affinity for nicotine. Although 
there was a considerable amount af non-specific binding in these assays, in all experiments 
we found a dose dependent displacement of tritiated nicotine by "cold" nicotine. In none of 
the experiments performed did we detect displacement of tritiated nicotine by any of the 
other compounds. 
Transdermal nicotine administration has clearly been shown to have therapeutic 
effects in ulcerative colitis by two large placebo controlled double-blind trials"·30. However, 
the evident risks of cardiovascular and neoplastic diseases associated with smoking and 
nicotine use strongly hampers the therapeutic application of nicotine. A better understanding 
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of the mechanism through which nicotine exerts its anti-inflammatory effects might enable 
the development of compounds with the desired anti-inflammatory effects while lacking the 
cardiovascular and carcinogenic effects. 
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III vivo effect of nicotine on cytokine production by human non-adherent 
mononuclear cells' 
Abstract - Ulcerative colitis (UC) is predominantly a disease of non-smokers and 
treatment with transdermal nicotine improves symptoms in UC patients, whereas 
smoking seems to have a deleterious effect in patients with Crohn's disease (CD). In 
CD the cytokine profile is of a dominant T-helper I (Thl) pattern whereas in UC the 
T -helper 2 (Th2) pattern predominates. To find an explanation for the beneficial 
effect of nicotine in UC and the deteriorative effect in CD we studied the ill vivo 
effect of nicotine on the IL-2, IL-1O and TNFa production by human cells. 
Eleven healthy male non-smokers were included in this study. The volunteers 
applied nicotine patches with a regulated release of 5 mg (day J and 2), 10 mg (day 
3 and 4) and 15 mg (day 5, 6 and 7) nicotine per day. 
Heart rate and blood pressure were recorded, nicotine and cotinine concentrations in 
plasma measured before and after 2, 4 and 7 days of treatment. Non-adberent 
mononuclear cells (NAC) were isolated from peripheral blood obtained from the 
subjects before and after 7 days of treatment. The NAC were cultured in the absence 
or presence of phytohemagglutinin for 48 hours. Total amount IL-2, IL-I0 and 
TNFa formed were measured in the supernatants using specific ELISA's. 
Treatment with nicotine caused a significant inhibition of IL-1O production by NAC. 
In contrast, nicotine patch treatment had no effect on the production of IL-2 and 
TNFa. 
'Based all: Stanley Madretsma, Leonieke M.M. Wolters, Jeanette P.M. van Dijk, 
Corne J.A.M. Tak, Colin Feyerabend, J.R. Paul Wilson, Freek J. Zijlstra. Europeall 
Journal of Gastroenterology & Hepatology 1996;8:1017-1020. 
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Nicotine ill vivo has an inhibitory effect on Th2 cell function as measured by 
inbibition of IL-IO production, but does not appear to have any effect on Thl cell 
function. 
9.1 Introduction 
Inflammatory bowel disease (lED) is a collective tenn for two distinct disease 
entities of unknown etiology, ulcerative colitis CUC) and Crobn's disease (CD). Both 
disorders are characterized by chronic inflammation of the gastrointestinal tract in which the 
T -helper (Thl and Th2) cell may play an important role. One of the current views is that 
IBD might result from an imbalance between the Thl and Th2 cell function, with Thl cells 
being overactive in CD and Th2 cells in UCI .,.'. This idea is based on the cytokine profIles 
found in IBD. In CD elevated levels of the Thl cell derived cytokines IL-2 and INFy are 
reported, whereas in UC we fmd elevated levels of IL-lO, produced by Th2 cells. 
Epidemiological studies suggest that exogenous factors may play a role in the 
pathogenesis of IBD and it has become clear that environmental factors such as cigarette 
smoking may modulate the course of both fonns of inflammatory bowel disease'·s". 
Smoking protects against ulcerative colitis and nicotine has a beneficial effect on the 
symptoms"'. The mechanisms through which nicotine exerts its effect are still unknown, but 
there is evidence that smoking influences the cellular as well as the humoral immune 
system9.IO.II,12.13.14. 
In order to fmd an explanation for the beneficial effect of nicotine in UC and the 
deteriorative effect in CD, we studied the ill vivo effect of nicotine on the cytokine 
production by human non-adherent mononuclear cells. 
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9.2 Subjects and methods 
Subjects 
This study was approved by the Medical Ethical Committee of the University 
Hospital Rotterdam. Eleven healthy male non-smokers (5 ex-smokers and 6 lifelong non-
smokers, mean age: 24 years) were included in the study after a detailed medical history to 
insure that none of the subjects were suffering from cardiovascular or other disorders. None 
of the subjects were taking medicines of any kind. 
After explanation of the aim and scope of the study heart rate and blood pressure of 
the volunteers were recorded before drawing 60 mI of venous blood. 
Treaflnent 
Each subject received 2 patches with a regulated release of 5 mg nicotine over a 
period of 16 hours, 2 patches with a release of 10 mg and 3 patches with a release of 15 mg 
nicotine per 16 hours. On day I and 2 single 5 mg patches were worn, on day 3 and 4 
single 10 mg patches, and on day 5, 6 and 7 single 15-mg patches. Patches were obtained 
from Phannacia, Sweden. There was a stepwise increase of the nicotine dose and the 
subjects applied the patches before going to bed to limit the side effects. 
Blood samples were obtained before and after 2, 4, and 7 days of treatment and 7 
days after cessation of treatment for measurement of the nicotine and cotinine levels in 
plasma. 
Isolation of mononuclear cells 
Mononuclear cells (MNC) were isolated from 60 mI heparinized venous blood 
immediately after blood sampling before the patches were applied, after 7 days of treatment 
and 7 days after cessation of treatment. The method used was a modification of the 
technique described by Boyum". Briefly, the blood was diluted 1: 1 with Phosphate 
Buffered Saline (PBS; Oxoid, U.K.) before fractioning it by a one-step Ficoll-Paque 
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gradient (phannacia, Sweden) centrifugation at 1100 g for 15 minutes at 20 0c. The 
interphase was washed in PBS and resuspended in Dulbecco's Modified Eagles Medium 
(DMEM) containing HEPES and foetal calf serum (Gibco, U.K.), supplemented with 
penicillin and streptomycin (Flow Lab, U.K.). 
Following isolation the MNC were incubated in culture medium for 90 minutes in a 
water saturated atmosphere of 37 °c containing 5 % Co,. Non-adherent MNC (NAC) were 
harvested by repeated rinsing of the culture flasks (Costar, U.S.A.) with DMEM. The 
viability of the cells, assessed by Trypan blue exclusion, was over 95 %. 
Characterization of non-adherentmononuciear cell fraction 
The leucocyte subpopulations present in the non-adherent MNC fraction were 
analyzed by FACS using the monoclonal antibodies Leu 4, Leu11 and Leul9 (Becton 
Dickinson, Mountain View, CA) that recognize CD3, CDl6 and CDI9 respectively. CDl4 
and CD20 positive cells were characterized by My 4 and B4 (Coulter Cytometry, Florida) 
Cytokine production 
Non-adherent MNC were cultured (2 x HI cellsl well) in 24 wells culture plates 
(Costar, Cambridge MA, USA) for 24 hours after which phytohemagglutinin (pHA: 10 
I'g/m1; Sigma Chernie, Belgium) was added to half of the wells followed by incubation for 
another 24 hours. The supernatants were harvested and stored at -80 °c until IL-2, IL-1O 
and TNFa concentrations were assessed by ELISA (lL-2: Medgenix, Belgium, IL-IO: 
Phanningen, U.S.A. and TNFa: Central Laboratory for Blood transfusions, The 
Netherlands). All incubations were perfonned in triplicate. 
Side effects 
Subjects were asked to grade possible side effects from 0 (none) to 5 (severe) at each 
visit. 
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Statistics 
The IL-2, IL-IO and TNFa production and hemodynamic parameters are expressed 
as mean ± SD (n = II). Statistical comparisons between control and nicotine-treated NAC 
were made by Wilcoxon paired t-test. A P <0.05 was considered significant. 
9.3 Results 
Nicotine and cotinine levels ill plasma 
The plasma nicotine and cotinine concentrations rose significantly during treatment, 
reflecting the nicotine dose applied. By the seventh day the plasma levels reached the 
maximal level of 10.2 ng/ml and 148.4 ng/ml for nicotine and cotinine respectively. 
One week after cessation of treatment the nicotine and cotinine concentrations were back to 
baseline values (table 9.1). 
Day Nicotine Cotinine 
0 0.2 ± 0.1 7.2 ± 12.8 
2 3.5 ± 1.0 41.5 ± 9.9 
4 6.9 ± 1.4 82.7 ± 16.4 
7 10.2 ± 2.4 148.4 ± 44.8 
14 0.3 ± 0.3 4.0 ± 5.3 
Table 9.1 Plasma nicotine and cotinine concentrations (nglmJ), mean ± SO 
(n = 11), before (day 0). during (days 2, 4 and 7) and seven days after exposure 
to transdennal nicoline. Samples were drawn approximately 11 hours after 
application of the patch. 
Characterization of NAC 
The non-adherent MNC fraction consisted primarily ofT-lymphocytes (table 9.2). 
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Cluster differentiation Percentage 
CD3 71.8 ± 2.1 
CDI6/CD56 14.7 ± 0.7 
CD20 7.7 ± 1.7 
CDI4 0.8 ± 0.1 
Not classified 5.1 + !.I 
Table 9.2 Percentage of different cell types comprising the 
non·adherent mononuclear cells.Celis were characterized using 
the monoclonal antibodies Leu 14, Leu 11, Leu19, B4 and My 4. 
Cytokine production 
The effect of nicotine on the IL-2, IL-IO and TNFa production by stimulated and 
non-stimulated human NAC was studied. Treatment with nicotine caused a significant 
inhibition of !L-IO production by non-stimulated NAC (pre: 275 ± 280 pg/ml) (Nicotine: 
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Figure 9.1 The effect of nicotine on IL·I0 production by non· 
slimulated NAC (mean ± SD) in pglml, (n = 11) (* P < 0.05) . 
IL·lO production was measured before (Pre), after 7 days exposure 
to transdermal nicotine (Nicotine) and 7 days after cessation of 
treatment (Post). 
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130 ± 155 pg/ml). This inhibitory effect was still evident 7 days after cessation of 
treatment (post: 85 ± 95 pg/ml) (figure 9.1). In contrast, treatment did not inhibit the 
PHA-stimulated IL-2, !L-IO and TNPu production. Par IL-IO the PHA-stimulated 
production before, after 7 days exposure to transdermal nicotine and 7 days after cessation 
of treatment was 1085 ± 1430 pg/ml, 775 ± 1010 pg/ml and 640 ± 450 pg/ml, 
respectively. The PHA-stimulated IL-2 levels were 2120 ± 830 pg/ml, 2115 ± 1375 pg/ml 
and 1545 ± 2805 pg/ml. Stimulation of NAC resulted in TNPu concentrations of 
4545 ± 935 pg/ml, 4055 ± 1440 pg/ml and 3760 ± 910 pg/ml respectively. 
Side effects 
Eight of the 11 subjects experienced some kind of side effects (5 out of 6 lifelong 
non-smokers and 3 out of 5 ex-smokers). In order of frequency the side effects were sleep 
disturbance or nightmares, itching, mild skin irritations, dizziness, nausea, chill, headache, 
tremor and vomiting. Although most subjects characterized the side effects as mild 
(score I), two individuals experienced severe dizziness and nausea, leading to vomiting in 
one subject. Most side effects were experienced during the first night after raising the 
nicotine dose from 5 mg to 10 mg and subsided with continuation of the treatment. The 
severity of the side effects was not related to the subjects smoking history, although both 
individuals who experienced severe side effects were non-smokers and more lifelong non-
smokers experienced side effects. Plasma nicotine and cotinine concentrations did not 
correlate with inhibition of cytokine production or side effects. 
The treatment had no effect on heart rate, systolic and diastolic blood pressure, nor 
did any of the subjects experience palpitations. 
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9.4 Discussion 
We chose to use a cell population consisting predominantly of T-cells in this study 
for two reasons. Recent studies have reported elevated levels of T-cell generated cytokines 
in inflanunatory bowel disease, with Crohn's disease displaying a Thl cell cytokine profile 
while ulcerative colitis is characterized by a Th2 cell cytokine profile. Another rmding 
indicating an important role for the T-cell in the pathogenesis of UC is the observation that 
appendectomy has a protective effect against UC. The appendix is a helper T-cell orgad'. 
Smoking has been indicated to influence the cellular as well as the humoral immune 
system,·to.II.Il.".14 and recent studies have shown nicotine to have a beneficial effect in UC'. 
Binding studies have demonstrated receptors with a high affruity for nicotine on human 
lymphocytes"'''. 
The results of this study show that nicotine ill vivo inhibits the IL-1O production by 
non-stimulated human NAC. This could indicate a functional inhibitioll of the Th2 cells, as 
this cytokine is primarily produced by Th2 cells. Recent reports have indicated an 
imbalance between Thl and Th2 cell function in mD, with the former being overactive in 
CD and the latter in UC. 
The inhibition of IL-1O production by nicotine could also account for the lower 
immunoglobulin levels reported in smokers"· I '.". Interleukin 10 is a very potent inducer of 
B-cell proliferation and differentiation. In SAC-activated as well as in CD40 system 
activated B-lymphocytes IL-1O has proven to be the most potent cytokine in the induction of 
IgA-, IgG- and IgM- productionl '. Experiments with anti-IL-1O treated mice have also 
provided evidence for the important role of !L-lO in immunoglobulin production''' 
Although no significant inhibition of !L-1O production by PHA stimulated NAC was 
detected, there is clearly a trend visible. 
We were not able to study the effect of nicotine ill vivo on the IL-2 and TNPa 
production by non-stimulated human NAC due to the fact that in the majority of cases the 
production was beneath detection level. The PHA stimulated production of these cytokines 
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was not inhibited by treatment with nicotine patches. These findings might indicate lack of 
effect on Thl cell function. 
The inhibitory effect of nicotine was still present 7 days after cessation of treatment. 
The effect even seems to be greater. In a prospective study Miller ef al. demonstrated that 
relative CD8 cell counts and the CD4 to CD8 ratio took three weeks to return to normal 
after smokers had stopped smoking". This finding indicates that nicotine also induces T-cell 
differentiation and by doing so has a greater effect on younger cells. If this is the case the 
effect of nicotine would be more evident when the subjects would have been treated for a 
longer period of time. For ethical reasons this was oniy allowed to be performed in UC 
patients. 
We conclude that nicotine ill vivo significantly inhibits the IL-IO production by Non-
stimulated human non-adherent mononuclear cells. 
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Chapter 10 
Summary, general discussion and directions for further research 
10.1 Summary 
Chapter 1 is a review of basic and clinical aspects of idiopathic inflammatory 
bowel disease. Idiopathic inflammatory bowel disease is a chronic relapsing inflammation of 
the human gastrointestinal tract or part of it. There are two main clinical entities, Crohn's 
disease and ulcerative colitis, with distinct differences but also with many similarities. 
Symptoms depend on the extent and seriousness of the inflammation and may vary 
from minor complaints to life threatening intestinal and extra-intestinal complications. 
Although the etiology remains obscure, epidemiological studies suggest a genetic 
susceptibility which causes inadequate immunological responses to environmental agents. 
Medical treatment of inflammatory bowel disease has progressed during the last decade. 
Current standard treatment consists of aminosalicylates and corticosteroids, either alone or 
in combination. A variety of alternative drugs are becoming available for patients with 
disease refractory to standard treatment. Of the newer drugs cyelosporin, azathioprine/6-
mercaptopurine and methotrexate are the ones at present most often used. 
Chapter 2 describes the synthesis, metabolism and anti-inflammatory effects of 
glucocorticoids. These are the most effective anti-inflammatory agents known. 
Glucocorticoids exert their actions after binding to specific receptors located in the 
cytoplasm. Binding of glucocorticoids to its receptor results in the down-regulation of the 
transcription of pro-inflammatory genes and up-regulation of the transcription of anti-
inflammatory genes. Glucocorticoids affect the functions and the number of inflammatory 
cells, and reduce the vascular permeability by influencing endothelial cell shape and 
contractility and membrane composition. 
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Glucocorticoids were first used in the treatment of ulcerative colitis during the 
nineteen-forties. For mild to moderate exacerbations the optimal dose was found to be 40-60 
mg of prednisolone daily. However, glucocorticoids do not reduce the rate of relapses. In a 
later stage it became clear that glucocorticoids are also effective in the treatment of acute 
exacerbations of Crobn's disease. The use of enemas has facilitated local treatment of 
inflammatory bowel disease, but it has not been able to abolish the systemic side effects 
entirely. Recently corticosteroids with a high first pass effect have been developed to 
decrease systemic effects without reducing local mucosal concentration. G1ucocorticoids do 
not only affect the immune system but also many other systems, causing various side 
effects. In order to reduce these side effects, rapidly metabolized topical glucocorticoids 
have been developed and are being tried in the treatment of inflammatory bowel disease. 
Chapter 3 is a report of ill vitro experiments in order to asses whether the inhibition 
of the stimulated production of TNFu, IL-6, PGE, and LTB, by human mononuclear cells 
depends on the number or the affinity of the glucocorticoid receptors of these cells. 
Glucocorticoid receptor number and affinity were determined using a whole cell binding 
assay with tritiated dexamethasone. 
A concentration dependent inhibition of TNFu, IL-6 and PGE, production was 
observed. Dexamethasone had no effect on LTB, production. A steroid receptor antagonist, 
RU486, significantly blocked the effect of dexamethasone, but no correlations were found 
between the inhibition of mediator release and affinity or receptor number. 
In Chapter 4 we investigated whether the variation in response to corticosteroids 
could be due to variation in number or affinity of glucocorticoid receptors (GR) on 
mononuclear cells (MNC). In order to test this hypothesis we assessed if GR-number and 
GR-affinity of MNC isolated from venous blood of IBD-patients not responding to 
corticosteroid therapy differ from those of healthy volunteers and IBD-patients who do 
respond to this type of therapy. 
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GR-content and K" for the three groups were respectively, healthy volunteers: 
4430 ± 340 sites per cell and 9.5 ± 0.7 runolll; responders: 3900 ± 210 siteslcell, 7.9 ± 
0.6 runolll; non-responders: 2450 ± 310 sites/cell, 6.0 ± 1.4 runoll!. Thus, mononuclear 
cells of mD-patients not responding to glucocorticosteroids have a low glucocorticoid 
receptor number. 
However, experiments with blood drawn from the same nomesponders 9 to 12 months later 
did not confIrm this rmding. A possible explanation for this discrepancy is that 
corticosteroid resistance in IBD is acquired and reversible, as seems to be the case in 
asthma. 
Chapter 5 gives an overview of pharmacological and immunological actions of 
nicotine. The effects of nicotine on the immune system of animals depend on the species 
tested, the age of the animals, duration of exposure and the level of exposure. Short-term or 
acute exposure generally results in limited effects which soon fade away after cessation of 
exposure. Chronic exposure on the other hand usually has a suppressive effect on the 
immune system. 
In humans smoking causes an increased leucocyte count in peripheral blood of which 
the extent depends on genetics, gender, age and the number of cigarettes smoked. On the 
other hand several studies have reported a decreased natural killer cell activity in leucocytes 
of smokers. The ill vitro synthesis of mediators of inflanunation and immunoglobulin 
production have been shown to be modulated by nicotine. 
Epidemiological studies have shown nicotine use to be associated with an increased 
incidence of certain disorders and a decreased incidence of others. The availability of 
nicotine gum and patches has made it possible to study the efficacy of nicotine in the 
treatment of the disorders last mentioned. These studies have shown significant clinical 
improvement. However, the risk of addiction and the cardiovascular side effects have 
restrained clinician from applying nicotine as a standard treahnent. 
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In chapter 6 we investigated the ill vivo effect of nicotine on lipid mediators and 
cytokines produced by colonic mucosa in mice. Colonic mucosa was obtained from 15 
BALB/c female mice. Six mice were treated with nicotine for 22 days and nine mice with 
placebo. The concentration of nicotine and cotinine in plasma reflected the dose of nicotine 
given. Colonic mucosa was homogenized in Krebs-Henseleit buffer and centrifuged. 
Mediators of inflammation were measured in the supernatant by radio immunoassay and 
ELISA. 
The synthesis of the lipid mediators such as the prostanoids prostaglandin 1'" 6-keto-
prostaglandin FI« and thromboxane B" the 5-lipoxygenase products leukotriene B, en C, 
and platelet activating factor is not affected, whereas the synthesis of the pro-inflammatory 
cytokines interleukin 16 and tumor necrosis factor u is significantly inhibited. 
Chapter 7 describes the results of a study in which the ill vitro effect of nicotine on 
IL-2 and TNFo: production by human mononuclear cells, isolated from peripheral blood 
from healthy volunteers was investigated. Non-adherent MNC were preincubated with 
varying concentrations of nicotine or prednisolone for 24 hours followed by addition of 
phytohemagglutinin. The concentrations of IL-2 and TNFu in the supernatant were 
determined by ELISA. 
Nicotine as well as prednisolone caused a significant inhibition of IL-2 and TNFu 
production. The maximum inhibition caused by nicotine was about 50 % of that caused by 
prednisolone and was reached at concentrations equivalent to nicotine levels measured in 
plasma of smokers. 
Chapter 8 reports the results of experiments performed to assess whether the 
receptors for nicotine present on human MNC are involved in the nicotine induced 
inhibition of cytokine production. Non-adherent MNC were preincubated in the presence or 
absence of two cholinergic nicotine receptor antagonists, hexamethonium and pancuronium, 
followed by the addition of nicotine and phytohemagglutinin (10 I'g/mi). The concentrations 
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of IL-2 and TNFa in the supernatant were detennined by ELISA. Furthermore, ligand 
binding studies and displacement experiments were conducted to confIrm the presence of 
receptors for nicotine on the MNC and to further characterize these receptors. 
Interleukin 2 and TNFa production was signifIcantly inhibited by nicotine. 
However, this inhibition could not be blocked by hexamethonium or pancuronium. The 
MNC had 2630 ± 350 nicotine receptors I cell (mean ± S.E.M.) with a I\, of 6.2 ± 1.4 
nmolil. The nicotine receptor present on the MNC had no affInity for any of the cholinergic 
agonists and antagonists tested. These results indicate that nicotine inhibits the production of 
IL-2 and TNFa by peripheral blood MNC via a non-cholinergic nicotine receptor. 
Chapter 9 describes the ill vivo effect of nicotine On the cytokine production by 
human non-adherent mononuclear cells. Ulcerative colitis is predominantly a disease of non-
smokers and treatment with transdermal nicotine improves symptoms in UC patients, 
whereas smoking seems to have a deleterious effect in patients with Crahn's disease (CD). 
In CD the cytokine profIle is of a dominant Thl pattern whereas in UC the Th2 pattern 
predominates. To fInd an explanation for the benefIcial effect of nicotine in UC and the 
deteriorative effect in CD, we studied the ill vivo effect of nicotine on the IL-2, IL-IO and 
TNFa production by human cells. 
Eleven healthy male non-smokers were included in this study. The volunteers 
applied nicotine patches with a regulated release of 5 mg (day 1 and 2), 10 mg (day 3 and 4) 
and 15 mg (day 5, 6 and 7) nicotine per day. Heart rate and blood pressure were recorded, 
nicotine and cotinine concentrations in plasma measured before and after 2, 4 and 7 days of 
treatment. Non-adherent mononuclear cells (NAC) were isolated from peripheral blood 
obtained from the subjects before and after 7 days of treatment. The NAC were cultured in 
the absence or presence of phytohemagglutinin for 48 hours. Total amount IL-2, IL-I0 and 
TNFa formed were measured in the supernatant using specifIc ELISA's. 
Treatment with nicotine caused a signifIcant inhibition of IL-IO production by NAC. 
In contrast, nicotine patch treatment had no effect on the production of IL-2 and TNFa. 
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Nicotine in vivo has an inhibitory effect on Th2 cell function as measured by inhibition of 
IL-IO production, but does not appear to have any effect on Thl cell function. 
10.2 General Discussion 
The etiology of inflammatory bowel disease remains unknown but recent studies 
suggest a dysfunctional inunune response to environmental agents. Susceptibility to 
development of this dysfunctional inunune response is probably genetically determined. 
Inflammation is the key pathological event in IBD and can be divided in three stages: 
initiation, perpetuation and development of tissue damage'. Mononuclear cells play an 
important role in all three stages. 
The medical treatment of inflammatory bowel disease is based on suppression of the 
inflammation"'. The substances mostly used are glucocorticoids. Although glucocorticoids 
have been effectively used in !he treatment of IBD for over 30 years now, the precise 
mechanisms through which they exert their anti-inflammatory effects is far from elucidated. 
An example for this is the remaining puzzle why some patients fail to respond to treatment 
with glucocorticoids (corticosteroid resistance). 
Failure of some patients to respond to treatment with corticosteroids'" has lead to 
efforts to fmd other substances with anti-inflammatory effects useful in the treatment of 
inflammatory bowel disease. Epidemiological studies have identified multiple substances 
which influence the course of IBD'. One of these factors is cigarette smoking which is 
associated with a decreased incidence of ulcerative colitis"'. This has lead to clinical trials 
with nicotine for active ulcerative colitis. 
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The aims of the experiments described in this thesis were to: 
1. Study the anti-inflammatory properties of glucocorticoids (part 2) and 
nicotine (part 3) by evaluating their effects on inflammatory mediator 
production by (human) MNC. 
2. Study the characteristics of the receptors for these substances in 
MNC. 
The studies described in the second part of this thesis were focused on finding an 
explanation for corticosteroid resistance. First we set out to demonstrate the importance of 
the glucocorticoid receptor in the exertion of the effects of glucocorticoids. Chapter 3 
clearly shows the inhibitory effect of dexamethasone on the production of inflammatory 
mediators to be glucocorticoid receptor mediated. Binding of the steroid receptor antagonist 
RU 486 to the glucocorticoid receptor blocks the effect of dexamethasone. 
The next step was to correlate the clinical effectiveness of glucocorticoids with the 
glucocoticoid receptor characteristics such as receptor number in the MNC and the affinity 
of these receptors. The experiments conducted with MNC isolated from blood obtained 
from IBD patients shortly (4 - 7 weeks) after these patients had proven to be responders or 
nooresponders yielded promising results. The nooresponders had a significantly lower OR 
number. However, these results were not reproducible with blood drawn from the same 
nooresponders 9 - 12 months later. Possible explanation for this is that the reduced OR 
number is acquired. Sher and associates found a diminished OR binding affinity in MNC 
from patients with corticosteroid resistant asthmalO• These authors reported the abnormal 
OR binding affinity to be acquired and cytokine-mediated, for it could be induced ill vitro 
by incubation of MNC from healthy donors in the presence of both IL-2 and IL-4". 
Furthermore, the diminished MNC OR binding affInity found in corticosteroid resistant 
asthma patients is reversible when the cells are incubated with medium alone, but 
sustainable by addition of IL-2 and IL-4 to the medium. 
The studies presented in the third part of this thesis showed that nicotine affects the 
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MNC ill vitro and ill vivo. Nicotine inhibits the IL-IB and TNFa production by mouse 
colonic mucosa (chapter 6). 
The effect of nicotine on human MNC was studied in vitro and ill vivo. The ill vitro 
production of the cytokines IL-2 and TNFa by human non adherent MNC was significantly 
inhibited by nicotine (chapter 7). Furthermore, these cells possess receptors for nicotine. 
Ligand binding studies showed these receptors to be of a non-cholinergic nature, which is in 
agreement with the finding that the effect of nicotine could not be blocked by 
hexamethonium and pancuronium, two cholinergic nicotine receptor antagonists (chapter 8). 
The next step was to study the in vivo effect of nicotine on human MNC. Treatment 
of healthy volunteers with nicotine patches resulted in an inhibition of IL-IO production, 
whereas IL-2 and TNFa production was not affected (chapter 9). We concluded that this 
might indicate a differentiated effect on Thl and Th2 cells, only inhibiting Th2 function. 
This would be in agreement with the epidemiological rmding that cigarette smoking is 
associated with a decreased incidence for ulcerative colitis and an increased incidence for 
Crohn's disease. In ulcerative colitis the cytokine profile is predominantly of a Th2 cell 
type, whereas in Crohn's disease it is of a Thl cell type. Experiments with genetically 
modified mice have contributed to the hypothesis that an imbalance between Thl and Th2 
function lays at the basis of the initiation phase of inflammatory bowel disease. IL-IO knock 
out and CD45RBbi,b scm mice who have a Thl cytokine profile develop a "CD-like", 
transmural inflammation of the small bowel"'''. IL-2 knock out mice on the other hand 
exhibit a more IIUe-like" inflanunation of their colonl4 , 
All in all the exact mechanisms through which nicotine exerts its anti-inflammatory 
effects are still unknown. The presence of receptors for nicotine on MNC implies a direct 
effect on these cells. However, this cannot be proven without the availability of an 
antagonist for this receptor. On the other hand ill vivo, nicotine also has an indirect effect on 
the inunune system through the endocrine system. Nicotine induces increased plasma levels 
of GC in animals 1S,16,17. as weB in humansl8,19,20 in a dose-dependent mannerl8,20. This is 
achieved by enhancing the release of corticotropin releasing factor (CRF) and ACTH from 
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10.3 Limitations of the applied methods 
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Mononuclear cells playa crucial role in inflammatory bowel disease. One could argue that 
the preceding statement is incomplete, in that in inflammatory bowel disease the MNC 
present in the gastrointestinal tract are the most important and not the MNC in the 
peripheral blood. 
The experiments described in this thesis have been performed using MNC isolated from 
peripheral blood and not from colonic mucosa, which is an obvious limitation. In order to 
obtain a sufficient number of MNC from colonic mucosa one would need to many biopsies 
of patients undergoing colonoscopy. This problem could be overcome by isolating cells 
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from mucosa from patients undergoing surgery. Patients being operated for a malignancy 
could be used as controls. It is however, a subject of debate whether MNC from patients 
with a colonic malignancy should be considered normal. In the second place, the 
inflammatory bowel disease patients responding to corticosteroid treatment will probably 
not be operated on, so mucosal MNC could not be obtained from responders. Thirdly, 
although the nonresponders almost always undergo surgery, their mucosal MNC will not be 
useful for these experiments, as these patients are usually on high dose corticosteroids at the 
time of the operation. 
10.4 Directions for future research 
During the last decade considerable progress has been made in understanding the 
pathogenesis of ffiD. This has led to the employment of clinical trials with substances which 
target specific effector mechanisms and mediators. These drugs have often shown little 
effectiveness, probably because inhibition of a specific pathway can be bypassed by parallel 
pathways. 
Glucocorticoids still form the heart of the medical treatment of ffiD. The rmding that 
corticosteroid resistance is associated with altered receptor characteristics should be further 
investigated. Attempts should be made to test the hypothesis that these alterations are 
acquired and whether they are cytokine-mediated as seems to be the case in asthma. 
One of the drugs which has demonstrated to be effective in active UC is nicotine',·,,·25. 
However little is known about the mechanisms through which nicotine exerts it effect in 
UC. We have shown nicotine to modulate cytokine production in vitro and in vivo and 
demonstrated receptors for nicotine on human MNC. Binding experiments should be 
performed to further characterize these receptors in MNC. In addition research should be 
done to study the second messenger mechanisms involved and to reveal mRNA encoding 
these receptors. A more detailed knowledge of the receptor involved may facilitate the 
development of new therapeutic approaches more acceptable than nicotine itself. 
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Samenvatting in het Nederlands (Summary in Dutch): 
In hoofdstuk 1 wordt een overzicht gegeven van basaal wetenscbappelijke- en 
klinische aspecten van chronische inflammatoire darmaandoeningen (IBD). De term IBD 
wordt gebruikt om twee ziekte entiteiten aan te duiden, namelijk de ziekte van Crohn en 
colitis ulcerosa, met duidelijke verschillen maar ook vele overeenkomsten. Bij beide 
aandoeningen gaat het om een chronische recidiverende ontsteking van het humane 
maagdarmstelsel of delen daarvan. Het klachtenpatroon is afhankelijk van de uitgebreidheid 
en ernst van de ontsteking en kan varieren van kleine ongemakken tot levensbedreigende 
intestinale en extra-intestinale complicaties. Hoewel de etiologie nog niet bekend is, zijn er 
aanwijzingen dat het gaat om een genetische predispositie met als gevolg een inadequate 
immunologische response op omgevingsfactoren. 
Gedurende het laatste decennium is er sprake van een geleidelijke vooruitgang van 
de medicamenteuze bebandeling van IBD. De behandeling bestaat thans uit corticosterolden 
en aminosalicylaten, afzonderlijk of in combinatie. Er komen steeds meer nieuwe middelen 
beschikbaar voor de behandeling van patienten met ontsteking niet-reagerend op standaard 
behandeling. Van deze nieuwe middelen worden cyclosporine, azathioprine! 
6-mercaptopurine en methrotrexaat het meest toegepasl. 
Hoofdstuk 2 beschrijft de synthese, het metabolisme en de anti-inflammatoire 
effecten van glucocorticosteroiden, de meest effectieve ontsteking remmers thans bekend. 
Glucocorticosteroiden werken via binding aan specifieke in het cytoplasma gelokaliseerde 
receptoren. Binding van GC aan de glucocorticoid receptor resulteert in tldown-regulatie" 
van de transcriptie van pro-inflanunatoire genen en "up-regulatie" van de transcriptie van 
anti-inflammatoire genen. Glucocorticosteroiden beinvloeden tevens de functie en het aantal 
van ontstekingscellen, en reduceren de permeabiliteit van de vaten door beinvloeding van de 
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vonn en contractiliteit van endotheelcellen. 
Glucocorticosteroiden werden in de jaren veertig voor het eerst in de behandeling 
van colitis ulcerosa toegepas!. De optimale dosis voor milde tot matige ernstige exacerbaties 
bleek 40-60 mg prednisolon per dag te zijn. De kans op recidiveren van de ontsteking wordt 
niet door GC belnvloed. In een later stadium bleken GC ook effectief in de behandeling van 
exacerbaties van de ziekte van Crohn. Gebruik van GC-klysmata heeft lokale behandeling 
van de ontsteking mogelijk gemaakt, maar de systemische bijwerkingen worden met deze 
vonn van therapie niet geheel voorkomen. Glucocorticosteroiden belnvloeden niet aileen het 
immuunsysteem, maar ook multipele andere systemen, met als gevolg niet aan het 
immuunsysteem gerelateerde bijwerkingen. Om deze systemische bijwerkingen te reduceren 
wordt steeds meer aandacht besteed aan het ontwikkelen van GC die lokaal toepasbaar zijn 
en snel worden gemetaboliseerd indien opgenomen. 
Hoofdstuk 3 is een beschrijving van ill vitro experimenten, uitgevoerd om vast te 
stellen of remming van de produktie van TNFa, IL-6, PGE, and LTB, door humane 
mononucleaire cellen afbankelijk is van het aantal of de affmiteit van de glucocorticoid 
receptoren in deze cellen. Glucocorticoid receptor aantal en affiniteit werden bepaald m.b.v. 
een receptor bindingsassays met getritieerd dexamethason. 
Dexamethason veroorzaakte een dosis-afbankelijke inhibitie van de produktie van 
TNFa, IL-6 en PGE" maar had geen effect op de LTB, produktie. De steroid receptor 
antagonist RU486 veroorzaakte een significante remming van het effect van dexamethason. 
Er werd echter geen correlatie gevonden tussen de inhibitie van mediator produktie door 
dexamethason en de affmiteit of receptor aantal. 
In de experimenten beschreven in hoofdstuk 4 werden de in hoofdstuk 3 beschreven 
technieken gebruikt om de hypothese te toetsen dat de variatie in respons op behandeling 
van IBD met glucocorticosteroiden het gevolg is van variatie in GR aantal of affmitei!. 
Onderzocht werd of de IBD patienten waarbij behandeling met GC niet effectief is gebleken 
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(nooresponders), verschilden qua GR aantal enlof affiniteit van de GR van de patienten 
waarbij deze vonn van therapie wei succesvol was ("responders"). Gemiddeld bezaten de 
MNC van de "nooresponders" een significant lager aantal GR in vergelijking tot de 
nresponderstl en de gezonde vrijwilligers. 
Bij herhaling van de experimenten met bloed afgenomen van de zelfde 
"nooresponders" 9 tot 12 maanden later bleek er geen sprake meer te zijn van een verlaagd 
receptor aantal. Het voorgaande kan mogelijk betekenen dat corticosteroid resistentie in IBD 
aiet aangeboren is, maar venvorven en het gevolg is van factoren zoals cytokinen. 
Soortgelijke bevindingen zijn beschreven voor corticosteroid resistente asbna patienten. 
Hoofdstuk 5 geeft een overzicht van de fannacologische en immunologische 
effecten van nicotine. De effecten van nicotine op het immuunsysteem van dieren is 
athankelijk van het soort, de leeftijd van de dieren, duur van blootstelling en de 
coneentratie. Blootstelling voor een korte periode heeft OVer het algemeen weinig invloed en 
de eventuele effecten zijn weer snel verdwenen na beeindiging van de blootstelling. 
Chronische blootstelling daarentegen heeft gewoonlijk een suppressief effect op het immuun 
systeem. 
Bij de mens veroorzaakt het roken van sigarenen een stijging in leukoeyten aantal in 
het perifere bloed, waarbij de mate van stijging athankelijk is van genetische factoren, 
geslacht, leeftijd en het aantal gerookte sigaretten. Meerdere studies hebben daarentegen een 
afoame van natural killer cel activiteit in de Ienkocyten van rokers beschreven. De ill vitro 
produktie van ontstekings mediatoren en immunoglobulinen kan door nicotine gemoduleerd 
worden. 
Epidemiologisch onderzoek heeft aangetoond dat nicotinegebruik geassocieerd is met 
een toegenomen incidentie van bepaalde aandoeningen en cen afgenomen incidentie van 
andere. Het beschikbaar komen van nicotine in niet-invasieve toedieningsvonnen (kauwgum 
en pIeisters) heeft de mogelijkbeid geschapen de effectiviteit van nicotine bij de behandeling 
van de Iaatstgenoemde groep aandoeningen te onderzoeken. Studies bij colitis ulcerosa 
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patienten met een actieve ontsteking laten een significante klinische verbetering zien. Het 
risico op verslaving en, de cardiovasculaire en carcinogene bijwerkingen beperken de 
toepasbaarheid van nicotine als standaard therapie. 
In hoofdslnk 6 wordt het in vivo effecI van nicotine op de produktie van lipide 
mediatoren en cytokinen door colon mucosa van muizen beschreven. Colon mucosa werd 
verkregen van IS BALBlc vrouwelijke muizen. Zes muizen kregen gedurende 22 dagen 
nicoline en 9 muizen kregen NaCI toegediend. Colon mucosa werd gehomogeniseerd in 
Krebs-Henseleit buffer en gecentrifugeerd. De concentratie gevormde 
ontstekingsmediatoren werd in het supernatant bepaald d.m. v. R.I.A. en ELISA. 
Nicotine had geen invloed op de vorming van de lipide mediatoren zoals de 
prostanoiden prostaglandine E" 6-keto-prostaglandine F
" 
en thromboxaan 13" de 
5-lipoxygenase produkten leukotriene B, en C, en platelet activating factor. Daarentegen 
werd de produktie van de pro-inflammatoire cytokinen IL-IJl en TNFa significant geremd. 
Hoofdslnk 7 beschrijf! de resultaten van een studie waarin de in vitro effecten van 
nicotine op de produktie van IL-2 en TNFa door mononucleaire cellen, gelsoleerd uil 
perifeer bloed van gezonde vrijwilligers, werd onderzocht. Niet-adherente MNC werden 
gedurende 24 uur gei'ncubeerd met verschillende concentraties nicotine of prednisolon, 
gevolgd door toevoeging van phytohemagglutinine. De concentratie gevormde IL-2 en 
TNFa werd in het supernatant bepaald d.m.v. ELISA. 
Zowel nicotine als prednisolon veroorzaakren een significante remming van de IL-2 
en TNFa produktie. De maximale inhibitie door nicotine bedroeg ongeveer 50 % van die 
van prednisolon en werd bereikt bij concentraties equivalent aan nicotine concentraties 
gemeten in plasma van rakers. 
Hoofdslnk 8 geef! de resultaten weer van experimenten uitgevoerd om te bepalen of 
de op humane MNC aanwezige receptoren voor nicotine betrokken zijn bij de door nicotine 
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geinduceerde remming van de cytokine produktie. Niet-adherente MNC werden 
gepreincubeerd in aan- of afwezigheid van 2 cholinergische nicotine antagonisten, 
hexamethonium en pancuronium, gevolgd door toevoeging van phytohemagglutinine 
(10 I'g/ml). De concentratie gevormde IL-2 en TNPa werden in het supernatant bepaald 
d. m. v. ELISA. 
Teveos werden ligand bindings- en verdringingsexperimenten uitgevoerd om de 
aanwezigheid van receptoren voor nicotine op humane MNC aan te tonen en nader te 
karakteriseren. 
Zowel de produktie van IL-2 als die van TNPa werd significant geremd door 
nicotine. Deze inhibitie kon echter noch door hexamethonium noch door pancuronium 
worden geblokkeerd. De MNC bezaten 2630 ± 350 nicotine receptoren per cel (gemiddelde 
± S.E.M.) met een K., van 6,2 ± 1,4 nmolli. De nicotine receptoren aanwezig op de MNC 
hadden geen affmiteit voor de geteste cholinergische agonisten en antagonisten. Deze 
resultaten suggereren dat het remmend effect van nicotine op de IL-4 en TNPa produktie 
door humane MNC via een niet-cholinergische nicotine receptor verloop!. 
Hoofdstuk 9 beschrijft de in vivo effecten van nicotine op de cytokine produktie 
door humane niet-adherente mononucleaire cellen. Elf gezonde mannelijke vrijwilligers 
kregen nicotine pleisters opgeplakt met eeo gereguleerde afgifte van 5 mg (dag 1 en 2), 10 
mg (dag 3 en 4) en 15 mg (dag 5, 6 en 7) nicotine per dag. Niet-adherente MNC (NAC) 
werden geisoleerd uit perifeer bloed van de vrijwilligers v66r en na 7 dagen behandeling. 
De NAC werden gedureode 48 uur in aan dan wei afwezigheid van phytohemaglutinine 
geincubeerd. De totale hoeveelheid gevormd IL-2, IL-IO en TNPa werd in het supernatant 
bepaald d.m. v. ELISA. 
Behandeling met nicotine veroorzaakte een significante inhibitie van de IL-IO 
produktie door NAC, maar had geen effect op de produktie van IL-2 en TNPa. 
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